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ABSTRACT 
 
 
The use of stents in the treatment of atherosclerosis leads to a potential risk of 
restenosis, caused by neointimal hyperplasia. Neointimal hyperplasia is mainly caused by 
an injury to the endothelial layer of the blood vessel followed by the proliferation of 
smooth muscle cells into the lumen of the blood vessel. To address this, we designed a 
magnetically-guided drug delivery system to locally deliver heparin to a stented artery. 
The nanoparticles were synthesized, characterized, and tested on relevant human cell 
lines.  
The particles were non-toxic to human smooth muscle cells, endothelial cells, and 
fibroblasts. They reduced the proliferation of the smooth muscle cells and increased the 
proliferation of endothelial cells at concentrations as low as 10 µg/mL. The particles also 
shifted the smooth muscle cells from their synthetic phenotype to their contractile 
phenotype. 
The capture of the nanoparticles by the stent struts, under relevant magnetic field 
and blood velocity was modeled using COMSOL Multiphysics. The coronary artery was 
modeled using a 2D axisymmetric model with stainless steel stent struts. A Magnetic 
field of 1 T was applied to magnetize the stent struts. Three different strut geometries 
were compared for their effect of the capture efficiency. The model had a capture 
efficiency 0f 34-42%, which is comparable to models using the same particle sizes.  
Ex vivo organ culture studies using porcine right coronary arteries were 
performed. The arteries were conditioned either statically in cell culture flasks or 
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dynamically in an organ culture bioreactor. Nanoparticles reduced intimal thickening in 
and expressed contractile properties in the treated arteries compared to the controls. 
We were successfully able to synthesize heparin-coated magnetic nanoparticles 
and achieve high heparin loading. Particle capture efficiency around the stent in the ex 
vivo porcine artery model was found to be similar to that predicted by the computational 
model. Consistent with the prior results of systemic heparin delivery, the nanoparticles 
reduce the proliferation and dedifferentiation of vascular smooth muscle cells while 
promoting endothelialization, both in vitro and ex vivo. Thus, these particles may be a 
promising treatment option for neointimal hyperplasia.  
 
.  
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CHAPTER 1 
INTRODUCTION 
Problem Identification: 
Currently the leading cause of death in both the United States and worldwide, 
cardiovascular disease, continues to grow in prevalence and overall healthcare burden. 
The number of cardiovascular deaths is expected to grow from 17.1 million in 2004 to 
23.4 million in 2030 (1). Coronary artery disease (CAD) is one of the major causes of 
morbidity and mortality in the developed world and it is expected to be one of the four 
leading causes of death by 2030 (1). CAD is mainly caused by atherosclerosis. 
Atherosclerosis is the build of plaque inside a blood vessel, usually an artery. It is mainly 
caused by smoking, diet, and aging, in addition to genetic factors (2).  
Current treatment options for CAD include percutaneous devices, which are 
associated with high rates of restenosis. Two of the main causes of restenosis are 
neointimal hyperplasia and thrombosis (2). Neointimal hyperplasia is mainly caused by 
the proliferation and dedifferentiation of vascular smooth muscle cells (VSMCs) when 
they are exposed to blood after an injury to the endothelial layer, where they undergo a 
phenotypic shift and change from their contractile phenotype to a synthetic phenotype (2, 
3). While drug-eluting stents (DES) are a step in the right direction in restenosis 
prevention, they are associated with late stent thrombosis, due to delayed 
endothelialization (1, 4). 
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We designed a drug delivery system to treat neointimal hyperplasia and prevent 
restenosis through preventing the proliferation and dedifferentiation of VSMCs and 
promoting endothelialization. We used heparin–coated magnetic nanoparticles to deliver 
heparin to a magnetizable stent under an external magnetic field. Heparin has been shown 
to reduce the proliferation of VSMCs and promote the proliferation of endothelial cells. 
Our preliminary in vitro and in vivo studies have shown that our heparin–coated 
magnetic nanoparticles are non-toxic (5). In vitro studies have shown that heparin–coated 
magnetic nanoparticles reduce the proliferation of VSMCs and increase the proliferation 
of endothelial cells (5).  
Specific Aims: 
Aim 1: To synthesize, characterize, and test heparin-coated magnetic 
nanoparticles on relevant human cell lines.  
• Approach 1.1: Synthesize heparin-coated nanoparticles and 
characterize their properties. Magnetic nanoparticles were synthesized, coated with 
amine-terminated polyethylene oxide, and heparin was attached to the amine ends. 
Another set of amine-coated particles were acquired from a supplier and modified with 
heparin. The core diameter, hydrodynamic diameter, and heparin loading for all the 
particles were measured. 
• Approach 1.2: Test the cell cytotoxic and phenotypic effects of the 
nanoparticles in vitro on vascular cells. Human aortic smooth muscle cells (hAoSMC), 
human umbilical vein endothelial cells (hUVEC), and human dermal fibroblasts (hDF) 
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were used to test the effect of the nanoparticles on toxicity, proliferation, differentiation, 
and phenotypes of these cell lines.  
Aim 2: Develop a computational model to assess magnetic field properties 
necessary to target nanoparticles to stents under physiologic flow conditions. A 
model that includes the layers of the arterial wall, blood flow, hemodynamic properties, 
magnetic nanoparticles, magnetic field, and a magnetizable stent was developed. The 
model tested different stent strut geometries, in addition to different assumptions on the 
capture efficiency of the nanoparticles. 
Aim 3: Validate the computational model using a dynamic flow experimental 
model. An ex vivo testing model was used to validate the results of the computational 
model and the in vitro studies. The model used a bioreactor and excised porcine coronary 
arteries, to simulate the dynamic in vivo environment dynamically, in addition to static 
testing.  
Significance: 
Historically, invasive surgeries to replace the stenosed blood vessel with a 
vascular graft were the only available solution to treat atherosclerosis. In the 1970s, 
balloon angiography was introduced to tackle the problem in a less invasive manner. 
Since then, many percutaneous interventions (PCI) have been introduced to offer non-
invasive options for the treatment of atherosclerosis. Despite having high success rates, 
percutaneous devices like vascular stents and balloon angioplasties have introduced new 
complications such as restenosis (3). Restenosis is caused by an injury to the endothelial 
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layer of the artery, which leads the smooth muscle cells in the medial layer to proliferate 
and switch their phenotype, in response to circulating growth factors. Current treatments 
for neointimal hyperplasia focus on prevention. One example is using drug-eluting stents 
(DES). DES reduced the incidence of in-stent restenosis (ISR) from 20-40% with bare 
metal stents to 3-20% with DES (6).  
While successful in reducing restonosis, DES use antiproliferation drugs 
commonly used in cancer, which have introduced new complications, such as late stent 
thrombosis (1, 4). While there have been good successes, the risks associated with PCI 
reveal the need for a more effective option. This option needs to be effective where DES 
fail and offer targeted treatment without new complications.  
Our design to treat neointimal hyperplasia is uses heparin-coated magnetic 
nanoparticles. The targeting method uses a magnetizable stent under an external magnetic 
field. Although in vitro studies give a physiological understanding of the safety and 
effectiveness of our drug delivery system, to fully understand the dynamics of the 
magnetic field with the nanoparticles, stent, and hemodynamics in a stenosed artery, we 
used a computational model to simulate the interactions between the different 
components of our drug delivery system (5). Our model focused on a human coronary 
artery, due to its prevalence in atherosclerosis and restenosis. The results from in vitro 
studies and computational modeling were validated in ex vivo models, using porcine 
coronary arteries. 
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Innovation: 
Studies on the in-vitro effects of antiproliferative drugs paired with magnetic 
nanoparticles have shown success on vascular smooth muscle cell, which proves their 
effectiveness in the treatment of neointimal hyperplasia (4, 7-9). However, there is a lack 
of understanding on the effect of the different drug delivery systems on endothelial cells. 
This gap in knowledge requires investigation of the role of any proposed system on the 
proliferation of endothelial cells, to prevent delayed endothelialization that would lead to 
late stent thrombosis (1, 4).  
Heparin has been shown to increase the proliferation of endothelial cells. 
However, heparin has short in vivo half-life and leads to internal bleeding complications 
if administered systemically in high doses. We developed a novel heparin-coated 
magnetic nanoparticle system to provide targeted delivery to the site of the stent, with 
lower side effects. The proposed approach evaluated the effectiveness of heparin coated 
magnetic nanoparticles on the proliferation of endothelial cells.  
Magnetic nanoparticles capture using magnetizable implants has been 
investigated, however particle with diameters smaller than 50 nm are rarely studied (10-
13). The proposed model analyzes the different assumptions at a smaller diameter, which 
sheds light on the particles behavior at this clinically significant level.  
The effect of stent strut geometries on the effectiveness of magnetically guided 
drug delivery systems had not been previously investigated. While dynamic ex vivo 
systems are common in tissue engineering applications, their use to test magnetically 
guided drug delivery systems has not been investigated.  
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CHAPTER 2 
 A REVIEW OF THE LITERATURE 
Introduction: 
Cardiovascular disease (CVD) continues to be the biggest cause of death in the 
industrialized world. The increase in the efforts to eradicate infectious diseases in 
developing countries is expected to lead to a rise in life expectancies in those areas, 
which in turn will increase the prevalence of cardiovascular disease. A major subset of 
CVD is coronary artery disease (CAD), mainly atherosclerosis. Interventions to treat 
atherosclerosis have introduced new complications, mainly restenosis. Restenosis is the 
re-occlusion of the blood vessel, following endothelial injury. Drug eluting stents have 
been introduced to tackle this problem, but they, in turn, introduced a new set of 
complications due to delayed endothelialization.  
Nanoparticles have been used in medicine for drug delivery, due to their large 
surface area over volume ratios. Magnetic nanoparticles offer a viable option for targeted 
drug delivery to magnetic and magnetizable implants. Heparin has been used as an 
anticoagulant for decades, however, its antiproliferative properties have been investigated 
in the past, but did not have much success when delivered systemically. 
Arterial Physiology:  
Arterial vessels are made up of three main components, the tunica intima, tunica 
media, and the tunica externa (also known as the adventitia) (figure 2.1) (1). In arteries, 
the medial layer tends to be thicker than that of veins. The composition of each layer 
varies slightly depending on the function of the artery. The tunica intima, which is the 
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innermost layer, is composed of a singular wall of endothelial cells, providing a smooth, 
anticoagulant boundary for blood flow (2). Outward from the tunica intima is the tunica 
media, composed largely of vascular smooth muscle cells (VSMCs) responsible for 
moderation of blood pressure by vasoconstriction and vasodilation (3). The outermost 
layer is composed of a combination of fibroblasts, elastic and collagenous fibers, and 
extracellular matrix components (figure 2.1). 
 
 
 
There are three types of arteries; elastic arteries, muscular arteries, and arterioles. 
Elastic arteries are characterized by large lumen diameters and the presence of elastin in 
their medial layer. An example of an elastic artery is he aorta. Muscular arteries are 
characterized by a tunica media that is almost entirely made of VSMCs (4). Muscular 
arteries are the most common type of arteries, which includes coronary arteries. 
Figure 2.1: The composition of arterial wall and a comparison between different 
types of arteries. The arteriole is scaled up 10x. Figure adapted from Biga et al. 
(49) without permission.  
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Arterioles are arteries with diameters smaller than 0.5 mm. Their medial layer is one 
eighths that of muscular arteries and they do not have a tunica externa (4) (figure 2.1).   
Atherosclerosis:  
Atherosclerosis is the buildup of plaque in the lumen of a blood vessel, which is 
caused by aging, smoking, diet, and genetic factors (figure 2.2). It is mostly prevalent in 
arteries, specifically medium sized arteries, most commonly coronary and femoral 
arteries. In coronary arteries, atherosclerosis leads to cardiovascular infarctions that could 
be fatal. Atherosclerosis is a chronic inflammatory response influenced by interactions 
between VSMCs, lipids, endothelial cells, inflammatory cells, and platelets (3). 
Atherosclerosis tends to develop over decades and is mostly prevalent in older patients. 
Historically, invasive surgeries to replace the stenosed blood vessel with a vascular graft 
were the only available solution to treat atherosclerosis. In the 1970s, balloon 
angiography was introduced to tackle the problem in a less invasive manner (2). Since 
then, many percutaneous interventions (PCI) have been introduced to offer non-invasive 
options for the treatment of atherosclerosis. 
Figure 2.2: Atherosclerotic plaque in an artery. Figure adapted from 
Elhadidy et al. (48) without permission. 
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Current Treatments Options:  
Despite having high success rates, percutaneous devices like vascular stents and 
balloon angioplasties have introduced new complications such as restenosis (2). 
Restenosis is caused by an injury in the endothelial layer of the artery leading the smooth 
muscle cells in the medial layer to proliferate and switch their phenotype, in response to 
circulating growth factors (3). Current treatments for neointimal hyperplasia focus on 
prevention. One example is using drug-eluting stents (DES). DES reduced the incidence 
of in-stent restenosis from 20-40% with bare metal stents to 3-20% with DES (2, 5). 
While successful in reducing restonosis, DES use antiproliferation drugs 
commonly used in cancer treatment, such as sirolimus and paclitaxel, which have 
introduced new complications, such as late stent thrombosis due to delayed 
endothelialization (6, 7). These drugs reduce the proliferation of the endothelial cells 
along with the smooth muscle cells, which slows down the healing of the vascular wall. 
One other reason DES have not been completely successful is due to the limited control 
over drug payload, dosage, or reloading, due to their limited surface area (7).  
Polymeric bioresorbable stents have also been explored as an alternative. They 
provide structural support to the blood vessel wall for a certain period of time then 
degrade. Animal studies for bioresorbable stents have shown higher rates of intimal 
hyperplasia and thrombosis due to inflammation (6). They also fail to provide the 
mechanical support necessary (8). In addition to the aforementioned complications, DES 
and bioresorbable stents increase the risk of clot formation due to portions of polymer 
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breaking off during implantation (8). Drug-eluting balloons have also been investigated. 
They, however, need extended inflation times, which induces vessel ischemia (9).  
Restenosis:  
In contrast to atherosclerosis, the development of restenosis is a rapid process that 
occurs in response to the implantation of PCI. It is caused by neointimal hyperplasia and 
thrombosis. Neointimal hyperplasia following stenting most often occurs as the result of 
damage to the interior vessel wall, the tunica intima (2, 3). Stresses to the vessel during 
stent placement may result in endothelial denudation and shielding from shear stresses 
necessary for proper endothelial functionalization (2). Following endothelial denudation, 
VSMCs within the tunica media are exposed to growth factors, allowing migration from 
the media into the lumen (6). Here they may experience excessive proliferation, similar to 
a tumor or keloid, occluding the blood vessel by cell growth (6). 
Factors Affecting Restenosis: 
Cellular Factors: In addition to proliferation, VSMCs shift from their contractile 
phenotype to a synthetic phenotype, which leads to restenosis (2) (figure 2.3). The 
contractile phenotype is characterized by the presence of different contractile markers, 
such as smooth muscle α-actin, smooth muscle myosin heavy chain, and calponin (1). 
After injury, VSMCs shift towards a synthetic phenotype and enter the cell cycle (1). 
Synthetic VSMCs show a higher rate of migration and proliferation, in addition, the 
expression of contractile proteins is reduced and extracellular matrix components are 
produced (1). These changes contribute to the thickening of the intima media.  
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During the early stages of embryonic vascular formation, VSMCs exhibit high 
rates of migration, proliferation, and extracellular matrix production (10). In healthy adult 
blood vessels, VSMCs only carry out their contractile functions. Upon injury, they 
dedifferentiate to their synthetic phenotype to repair the blood vessel, by producing 
extracellular components including collagen and elastin (10). This process contributes to 
the formation of restenosis.  
 
 
Figure 2.3: Comparison between VSMC phenotypes. Figure adapted from 
Rensen et al. (33) without permission. 
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Although restenosis is caused predominantly by the proliferation and migration of 
VSMCs, the roles played by endothelial cells and fibroblasts cannot be ignored. 
Endothelial cells in the tunica intima act as a selectively permeable barrier to prevent 
contact between VSMCs and growth factors circulating in the blood (2). Consequently, 
the endothelial layer inhibits intimal hyperplasia (2). Contrary to endothelial cells, 
fibroblasts role in restenosis is not well understood, however, studies have found that 
after injuries to the endothelial layer, myofibroblasts have been located in the adventitial 
layer (11). These fibroblasts have been found to express smooth muscle cell markers, 
such as smooth muscle actin and vimentin (11). 
Mechanical Factors: Restenosis rates have been related to many factors; stent or 
balloon material, biocompatibility, flexibility, surface properties, deployment force, 
presence of antiproliferation drugs, stent strut design and geometry, stent placement, 
shear stress, and the size of the blood vessel (12). All these factors affect the re-
endothelialization of the arterial wall and in turn affect the vascular smooth muscle cell 
proliferation. While each of these factors has a distinct effect on the stenosis of the 
arteries, they all interact with each other and we rarely see the distinct role of one player 
in the formation of intimal thickening.  
Multiple studies have shown the relationship between mechanical forces and the 
formation of restenosis in stented arteries. In bare metal stents, hemodynamics affects the 
shear stress on the endothelial layer, which affects the mechanotransduction and causes 
intimal thickening. In drug-eluting stents, the stent struts come in contact with the 
endothelium and delay its healing leading to late stent thrombosis. Research has shown a 
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relationship between stent geometries, hemodynamics, shear stress, endothelialization, 
and intimal thickening.  
The endothelium usually inhibits thrombogenesis because endothelial cells 
express an anticoagulant phenotype. After a stent is implanted, it forms a wall along with 
the blood vessel creating a new boundary for the blood flow. This new boundary changes 
the blood flow to try to separate around the strut. High shear rates have been proven to be 
ideal for endothelialization. Higher shear rate levels have been found over thick and 
nonstreamlined strut surfaces, which promotes endothelialization (12). Lack of proper 
endothelialization causes higher risks of stent thrombosis or neointimal hyperplasia 
leading to in-stent restenosis. Endothelial cells between stent struts are affected by 
changes in hemodynamics, which can also affect the results of drug-eluting stents (13). 
When the endothelium is injured, it is coated with activated platelets. Leucocytes are 
attached to the platelets by adhesion molecules then secrete growth factors and cytokines 
that activate vascular smooth muscle cells dedifferentiation and proliferation, which 
causes neointimal hyperplasia (14). 
1. Shear Stress: Shear stress has been one of the main mechanical factors to 
affect restenosis rates in stented vessels, due to its relationship with all the other major 
factors. Shear stress is identified as the force per unit area produced by blood flow when 
it comes in contact with the endothelial layer (13). The interactions between the blood 
flow and the endothelium induce mechanotrasnduction signals, which convert mechanical 
forces into chemical signals, which in turn affects arterial development, homeostasis, and 
adaptation (13). The interactions between shear stress and the endothelial layer also play 
 
16 
 
a major role in many cardiovascular pathologies, such as atherosclerosis, restenosis, 
hypercholesterolemia, diabetes, and hypertension (13). Higher shear stress has been 
shown to promote adaptive dilatation and structural remodeling of the blood vessel, 
which is associated with less intimal thickening. Changes in shear stress affect the 
signaling and gene expression of endothelial cells and vascular smooth muscle cells, 
which in turn adapt to shear stress by altering vessel architecture (14). 
Wentzel et al. (15) developed a model that combined 3D models of patients’ 
blood vessels and computational fluid mechanics to show the relationship between shear 
stress and neointimal growth. For their data collection, they looked at fourteen patients 
six months after stent implantation. They evaluated a model to test the hypothesis that 
regions with low shear stress experience neointimal thickening. To test their hypothesis, 
they used a three-dimensional reconstruction tool, ANGUS, which uses angiography and 
ultrasound images combined with ECG data to reconstruct the blood vessel geometries. 
They combined their 3D models with computational fluid dynamics models to construct a 
more efficient, patient specific model. They compared the shear stress and neointimal 
thickening data for each patient before and after stent implantation and six months after 
implantation. For measuring neointimal thickness, the reconstructed 3D models were 
used to measure the thickness of the vessel wall at implantation and six months after.  
2. Stent Geometries: Stent design and geometries have been a major interest 
of researchers in the past few years. With the shift in the percutaneous device market 
from bare metal stents to drug-eluting stents, patients and clinicians had high hopes for 
getting rid of the risk of restenosis. Although drug-eluting stents reduced that risk, they 
 
17 
 
did not demolish it completely, which led to a closer look at stent designs and geometries 
to analyze how they affect wall stresses, neointimal thickening, and hyperplasia. A few 
factors affecting this are, strut thickness and design, number of cross sections, cross-
sectional shape, and stent length (14).  
Stent strut design creates disturbances in blood flow, which delays 
endothelialization and causes late stent thrombosis (13). The endothelial cells between 
the stent struts have been shown to be affected by the hemodynamics in the stented blood 
vessel (13). Changes in flow patterns have been shown to affect platelet and 
inflammatory cell transport, which in turn affects endothelialization.  
He et al. (16) developed a 3D CFD model to compare four different stent strut 
designs with and without longitudinal connectors to compare the effect stent geometries 
have on wall shear stress and flow separation and how they affect thrombosis and 
neointimal thickening. In their model they focused on three parameters; strut 
interspacing, amplitude or spacing between concave and convex portions of the same 
strut, and the strut radius of curvature. The four different strut designs looked at are 
shown in figure 2.4 (16). They did not model currently available strut geometries to allow 
for a variation in the designs that could be used for future designs. They also considered 
two different shear stress flow conditions: high and low.  
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Their (16) model used 3D Cartesian geometry with a focus on the near-strut parts 
of the artery. To simplify their model, they only used two adjacent struts in the axial 
direction.  
The study found that designs without axial connectors are more hemodynamically 
beneficial because they seem to be closer in geometry to normal physiologic arterial wall. 
While it is theoretically possible to simulate a stent without connectors, it is not 
applicable in stent design due to the mechanical support they provide for the artery. The 
study has also found that designs with larger interstrut spacing and smaller spacing 
between concave and convex portions had more benefit from a hemodynamic point. The 
change between high and low flow conditions did not seem to affect the flow 
characteristics in this model.  
Figure 2.4: Stent strut geometries investigated by He et al. (16). 
Adapted without permission. 
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Jimenez et al. (12) looked at the hemodynamics in stented blood vessels using six 
different streamlined and nonstreamlined strut designs with three different sizes. Their 
study analyzed the effect of both shape and size of stent strut on the blood flow, 
endothelialization, and intimal thickening in a stented vessel. They used a computational 
fluid dynamics model to analyze their data. They used rectangular and circular strut 
designs with three different length to width ratios for each. The different strut geometries 
used can be seen in figure 2.5 (12). 
 
 
Their results proved the relationship between the stent strut geometry and size and 
shear stress and endothelialization. They showed a reduction in the shear stress values 
when the thickness of the rectangular strut was decreased. Circular designs showed lower 
shear stress than rectangular ones.  
 
 
Figure 2.5: Stent strut geometries investigated by Jimenez et al. (12). 
Adapted without permission. 
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Nanoparticles in Vascular Applications: 
 Nanoparticles have been used in medicine as drug delivery devices for various 
applications (17). The large surface area to volume ratio allows the delivery of sufficient 
amounts of drug to a specific site (18). They also provide targeted delivery options for 
drugs with adverse systemic effects. One targeted delivery method is using magnetically 
guided delivery systems, which primarily use magnetic nanoparticles.  
One of the largest investigated uses of nanoparticles in medicine is their use in 
imaging. Targeting nanoparticles to a specific location allows for better plaque imaging 
using commonly used imaging modalities. Varvara Karagkiozaki (19) summarized the 
investigated nanoparticle systems used for cardiovascular imaging (table 2.1).  
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Table 2.1: A summary of vascular targets used with different types of nanoparticles 
used for their targeting by imaging modalities and of the payloads and surface 
ligands used with them (19, 50-61). Adapted from Karagkiozaki (19) without 
permission. 
Abs=antibodies, CREKA=cysteine-arginine-glutamic acid lysine-
alanine, CT=computed tomography, DTPA=diethylene triamine pentaacetic 
acid, Gd=gadolinium, LDL=low density lipoprotein, LOX-1=LDL- 
receptor, MRI=magnetic resonance imaging, PEG=polyethylene 
glycol, PET=positron emission tomography, SPIO’s=small superparamagnetic iron-
oxide nanoparticles, USPIOs=ultrasmall superparamagnetic iron oxide NPs, VCAM-
1=vascular cell adhesion molecule 1, SPECT=single-photon emission computed 
tomography. 
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Nanoparticles in Restenosis: 
In addition to imaging, nanoparticles have been used in cardiovascular 
applications to prevent restenosis. Nanomedicine applications to prevent restenosis can 
be split into two categories: preventing VSMC proliferation and promoting 
endothelialization. It can also be divided into drug therapies, gene therapies, and 
endothelial cell therapy (6). Yin et al. lay out a list of most of the currently researched 
therapies. Some groups are investigating nanoparticle-eluting stents, which can have 
great potential, but still face a limited surface area limitation and risk of thrombosis. The 
major factors that affect a drug delivery device are the drug or therapeutic agent, the 
targeting moiety, and the loading method.  
Gu et al. (20) investigated using layered double hydroxide (LDH) nanoparticles 
with low molecular weight heparin (LMWH), as a therapeutic agent. The LDH particle 
design has a sandwich-like structure following the formula [M2+1-xM3+x(OH)2]x+(An-
)x/n.mH2O, where M2+ is a divalent metal cation, M3+ is a tivalent metal cation, and An- is 
an anion. M3+ replaces M2+, hydroxide layer becomes positive, balanced by exchangeable 
anion and an anionic drug replaces the anion. For their specific design, they used 
magnesium as a divalent metal cation, aluminum as a trivalent metal cation, and chlorine 
as an anion, with LMWH being the anionic drug. They did not specify a targeting moiety 
or method in their studies, however their in-vitro studies showed promising results.  
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Cicha et al. (21) summarize some other investigated factors used to prevent 
restenosis (table 2.2). 
  
Magnetic Nanoparticles: 
Magnetic nanoparticles have been used for different medical applications over the 
years. These applications include MRI contrast agents, magnetically guided drug delivery 
systems, hyperthermia therapy for cancer treatment, and magnetic separation (22).  
A particle is superparamagnetic when it is small enough to be composed of a 
single-domain, and there is sufficient thermal energy in the system to randomize the 
moments of an assembly of particles so no bulk magnetization is observed in a defined 
time period (23). How small a particle needs to be depends on the composition. The 
Table 2.2: Targets for nanoparticle therapy in cardiovascular disease (20). 
Adapted without permission.   
NP=nanoparticles, NOX=NADPH oxidase, PECAM=platelet-endothelial 
cell oxidation molecule, SMC=smooth muscle cell, SR-A=scavenger 
receptor type A. 
(38) 
(40) 
(41) 
(43, 
44) 
(57) 
(58) 
(59) 
(60) 
(61) 
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factors affecting the superparamagnetic diameter (RSPM) of the nanoparticles are shown in 
the following equation (23): 
                                                   RSPM=∛6 𝑇𝑇𝑘𝑘𝐵𝐵𝐾𝐾                                              
Where T is temperature, kB is Boltzman’s constant, and K is the anisotropy 
constant of the material.  
Magnetophoretic targeting is a targeting technique that uses the high saturation 
magnetization of the particles to magnetically attract them to a specified area using an 
induced field gradient. This is particularly useful for in vivo applications because the 
particles will only respond to an externally applied field, which can be targeted to a 
specific region(24-28).  
Chorny et al. (7) designed PLA paclitaxel-loaded magnetic nanoparticles to be 
delivered to a stented artery. They used uniform-field-induced magnetization to target the 
particles using a magnetized 304 stainless steel stent. They performed animal studies on a 
rat carotid stenting model. Their results show an inhibition of in-stent restenosis at low 
doses of their nanoparticles.  
Rathel et al. (9) investigated the use of lipid microtubules loaded with rapamycin-
coated superparamagnetic nanoparticles. They used a CoCr magnetizable stent with 
nickel plating. The stent is magnetized using an external neodymium magnet. Magnetic 
microtubules help capture the particles by the stent. In-vitro studies of these particles 
show promise in inhibition of VSMCs proliferation.   
Uthamaraj et al. (29) investigated delivering endothelial outgrowth cells to the 
stenting site to promote endothelialization. They used a magnetite core and a PLGA shell 
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that were uptaken by the cell. They used a magnetizable 2205 stainless steel stent for 
targeting and a neodymium magnet to magnetize it. They also performed animal studies 
using a pig model, which showed some success in a short period of time.  
Drugs Used in Restenosis Prevention: 
 
 
While other factors play an important role in the safety and efficiency of a 
nanoparticle drug delivery system, the drug or therapeutic agent used is of utmost 
importance. To compare the effect of different discussed drugs, we need to understand 
their effects of the cells cycle. Rapamycin or sirolimus is an immunosuppressive and 
antiproliferative drug. It blocks G1 to S cycle progression by inhibition of mTOR (2). 
Paclitaxel stabilizes microtubules to inhibit cell division in both G0/G1 and G2/M phases 
(2). Heparin is an anticoagulation and antiproliferation drug that causes G1 phase arrest 
Figure 2.6: The effect of different drugs on the cell cycle of VSMCs. 
Adapted from Yin et al. (6) without permission.  
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(30). Endothelial Cells promote the differentiation of VSMCs from synthetic to 
contractile phenotype through activating the AKT pathway (1).  
Yin et al. (6) looked at the different drugs used to treat neointimal hyperplasia in 
detail and discussed the effect of each of them and which family they belong to (figure 
2.5). They also discuss the different targeting drug delivery systems used to treat 
neointimal hyperplasia and their success.  
Heparin:   
Heparin is a sulfated glycosaminoglycan comprised of repeating units of 
glycosamine and uronic acid. (20, 31) In addition to its anticoagulation properties, 
heparin has been shown to inhibit the proliferation of VSMCs by Clowes et al. (32) in 
1977. Several studies since then (2, 3, 33-36) have shown heparin to reduce the 
proliferation, migration, and dedifferentiation of VSMCs and to promote 
endothelialization, to accelerate healing (3, 34, 37). Heparin affects growth and 
proliferation of VSMCs in phase G1 in the cell cycle. It inhibits the activation of mitogen 
activated protein kinase (MAPK) which in turn suppresses transcription factors needed 
for the proliferation and migration of VSMCs (20, 30).  
Heparin, however, is a negatively charged molecule, with a molecular weight of 
12,00-18,000 Da, and has a half-life of 1-5 hours. This makes the systemic delivery of 
heparin inefficient and causes undesirable side effects (38). Low molecular weight 
heparin (LMWH) has been shown to have longer half-life and reduced side effects 
compared to regular heparin (20).  
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Modeling: 
Computational modeling allows us to perform multiple quantitative analyses on a 
system and compare different inputs and factors to optimize a system. It helps us perform 
these analyses faster, cheaper, and more efficiently. It also gives us control over multiple 
factors and allows us to compare theoretical models to physiological and pathological 
cases. For magnetically-guided drug targeting (MDT) for the prevention of restenosis, 
models of blood vessels provide a detailed look at the mechanics of the interactions 
including hemodynamics, velocity, shear stress, external magnetic field, stent geometry 
and magnetic properties, and the magnetic drug carriers. A few groups have studied the 
effect varying these properties has on the capture efficiency of the particles.  
 
Most models studying MDT systems to blood vessels assume incompressible, 
Newtonian flow (39-42). The forces acting on the particles in the majority of the models 
Figure 2.7: Schematic of a MDT system using a stent. Figure 
adapted from Chorny et al. (47) without permission.  
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were Brownian motion, drag force, and magnetic force, with the assumption that inertia, 
gravity, and buoyancy being negligible (41, 43). Figure 2.6 shows the basic design of a 
MDT model using a stent.  
Chen et al. (41) modeled nanoparticles with radii varying from 0.5 µm to 20 µm, 
under a magnetic field ranging from 0.05 to 1.2 T. Unsurprisingly, particles with larger 
diameters under stronger magnetic fields had higher capture efficiencies, which was as 
high as 60%. They also compared the capture for different stent and particle materials. 
Iron particles achieved higher capture efficiencies compared to magnetite particles and a 
stainless steel 409 stent had higher captures than a nitinol stent.  
Wang et al. (40) had the widest ranges in comparison for their values. They 
compared magnetic fields in the range of 1-10 T and particle radii ranging from 10 to 500 
nm. While their results were comparable to what was seen before, it is important to note 
that they are one of the few groups to model a MDT system with a particle radius smaller 
than 100 nm. At 10 nm, they achieved a capture efficiency of 20%, under a magnetic 
field of 1 T.  
In their study, Mardinoglu et al. (39) analyzed capture efficiency in stretched 
vascular wall, which represents a stented artery more accurately. They modeled particles 
with a diameter of 0.86 µm, under a field of 0.15-0.6 T. The system performance 
decreased by 10% in the stretched vessel than the non-stretched one.  
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Ex-vivo: 
Bioreactors are commonly used in tissue engineering research to simulate in vivo 
environments to give stem cells the mechanical signals needed to differentiate to the 
required cell type. They provide all the in vivo clinical conditions, including 
hemodynamics and blood pressure, ex vivo. Additionally, a bioreactor for arterial organ 
culture is used to simulate the in vivo conditions to test a drug delivery system. The role 
of mechanotransduction is important in the development of both atherosclerosis and 
restenosis. Dynamic flow environments have been used previously to study the effect of 
mechanical forces on vascular pathology. An ex vivo model allows for a low cost way of 
testing different vascular percutaneous devices, with control over more variables such as 
blood pressure and blood vessel size. It is also a method to replace, reduce, and refine any 
in vivo studies needed.  
The use of dynamic ex vivo organ culture models has been assessed in the past. 
Carere et al. (44) used an ex vivo model of the coronary artery to study angioplasty 
injuries. Han et al. (45) assessed the role played by hypertensive pressure on contractile 
responses in common carotid arteries. Perée et al. (46) studied the effects of balloon 
angioplasty on carotid arteries. All these studies have validated that the use of ex vivo 
dynamic models gives a unique insight into arterial physiology and pathology in response 
to mechanical signals, that cell culture alone cannot provide. 
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CHAPTER 3 
AIM 1.1: PARTICLE SYNTHESIS AND CHARACTERIZATION 
Introduction:  
Nanoparticles have been used in medicine as drug delivery devices for various 
applications (1). The large surface area to volume ratio allows the delivery of sufficient 
amounts of drug to a specific site (2). Studies on the in vitro effects of antiproliferative 
drugs paired with magnetic nanoparticles have shown success on vascular smooth muscle 
cell, which may make them good candidates for the treatment of neointimal hyperplasia 
(3-6). In addition, small animal studies have shown that magnetic nanoparticles may be 
able to be targeted to stents with external magnetic fields (2, 4). However, there is a lack 
of understanding on the effect of the different drug delivery systems on endothelial cells. 
For instance, these drug and magnetic nanoparticle systems used drugs similar to those in 
DES, which are known to cause delayed endothelialization of the vessel (3, 7, 8). 
It is important to understand the role of any proposed drug system on the 
proliferation of endothelial cells, to prevent delayed endothelialization that would lead to 
late stent thrombosis (3, 9). Heparin has been shown to reduce VSMC proliferation and 
dedifferentiation (10-16). It has also been shown to promote endothelialization, to 
accelerate healing (10, 12, 13, 17). However, heparin has a very short half-life in the 
body limiting its efficacy in vivo (18). In addition, systemic delivery of high doses of 
heparin is associated with bleeding risks (18). 
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To address this, we developed and tested novel heparin-coated magnetic 
nanoparticles to provide targeted delivery to the site of the stent, under an external 
magnetic field. This chapter details the synthesis and characterization of two sets of 
batches of nanoparticles. For the first set, the core particles were synthesized and 
modified using a synthesized polymer, before the attachment of heparin (figure 3.1). For 
the second set, amine-terminated nanoparticles were bought from a supplier and heparin 
was attached to them. 
 
Materials and Methods:  
Iron oxide nanoparticle synthesis (set 1): Iron (III) acetylacetonate (Strem Chemicals, 
99%) and oleic acid (Alfa Aesar, 90%) were combined in a 1:15 molar ratio in a 3 –neck 
round bottom flask. The flask was input into a solder bath at 370oC, with overhead 
stirring and N2 purging at 0.1 L/min. for 4 hours. The reaction was quenched by 
removing from the metal bath and letting it sit at room temperature. The nanoparticles 
Figure 3.1: A schematic of the nanoparticle synthesis and 
functionalization processes. 
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were suspended in hexanes and precipitated with an ethanol (Fisher Scientific, anhydrous 
92.7%) and acetone (BDH, 99.5%) mixture and magnetically separated four times. 
Finally, the particles were suspended in chloroform (BDH, 99.8%). 
Ligand exchange (set 2): After the synthesis of the magnetite core, a 5000 g/mol 
heterobifunctional, dopamine-terminated polyethylene oxide (PEO) polymer was 
synthesized as previously published (19). The PEO polymer was attached to the 
nanoparticles through a ligand exchange process, to reduce their toxicity. The size of the 
polymer was chosen to prevent the aggregation of the nanoparticles, by providing 
colloidal stability (20). The polymer was synthesized using a living anionic ring opening 
polymerization of ethylene oxide with potassium bitrimethylsilylamide as an initiator and 
methane sulphonyl chloride was used to terminate the reaction. The resulting polymer 
was then modified with dopamine hydrochloride to add dopamine groups to the end to 
attach to the magnetite particle surface and HCl was used to deprotect the amine ends. 
The polymer synthesis and modification process is shown in figure 3.2.  
The particles suspended in chloroform at approximately 3 mg/mL were injected 
into scintillation vile containing previously described PEO polymer suspended in 
chloroform at approximately 40 mg/mL, with a septum cap under sonication. The 
injection process was done over a 30-minute period then allowed to sit under sonication 
for another 30 minutes. The nanoparticle-PEO solution was then allowed to sit for four 
days. After four days, chloroform was removed using rotary evaporation process. The 
nanoparticles were then resuspended into hexanes, sonicated, magnetically separated, and 
resuspended in chloroform and allowed to sit for 2 more days. The washing process was 
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repeated three times. After rotary evaporation for the third time, the particles were 
suspended in DI water. They were sonicated briefly to ensure breaking any large 
aggregates, then they passed through a 0.22 µm nylon syringe filter. The particles were 
centrifuged at 10,000 RPM for 10 minutes, the supernatant was decanted, and the 
nanoparticles were dispersed in DI water. To get rid of excess polymer, the particles were 
filtered through 50 kDa centrifugal filter units (Millipore). 
 
Heparin Attachment (both sets): Amine-functionalized iron oxide (II,III) magnetic 
nanoparticles (Sigma-Aldritch,10 nm) were purchased from supplier (set 2).  Amine-
functionalized nanoparticles were mixed with heparin at a 1:3 molar ratio. The aqueous 
particle solution was added to a low molecular weight heparin (LMWH, MP Biomedical), 
N-hydroxysulfosuccinimide (sulfoNHS, Thermo Scientific), and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, TCI Chemicals) solution, with 
excess sulfoNHS and EDC. The carboxylic acid groups of the LMWH were then attached 
to the primary amine groups on the nanoparticle ligand through a sulfoNHS/EDC 
Figure 3.2: Synthesis and modification of heterobifunctional PEO polymer. 
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chemical reaction. The solution was allowed to sit on a shake plate for seven days to 
allow reaction. To get rid of excess LMWH, sulfoNHS, and EDC, the particles were 
filtered through 50 kDa centrifuge filter units.  
Characterization: To characterize the size of the magnetic core of the 
nanoparticles (set 1), a Hitatchi H7600 transmission electron microscope (TEM) was 
used. Dynamic light scattering (DLS) using a Malvern Nano ZS zetasizer with a 633 nm 
laser was used to measure the hydrodynamic diameter of the nanoparticles (both sets) 
after functionalization with the amine and the heparin. Dimethylmethylene blue (DMMB) 
assay was used to quantify the heparin loading onto the nanoparticles (both sets), where 
absorbance was measured at 530 nm using a microplate reader. When 1,9-
dimethylmethylene is bound to sulfated glycosaminoglycans, it undergoes a shift in the 
absorption spectrum around 525nm (21). Raw heparin was used to obtain a standard 
curve and calculate the heparin loading per mass of particle.  
Results: 
Figure 3.3: TEM image of uncoated iron oxide particles. (Scale Bar 
=100nm) and a histogram of nanoparticle magnetic core diameter 
distribution. Average particle diameter was found to be 13.4 +/- 1.4 nm. 
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The synthesized nanoparticles, schematically shown in figure 1A, include a 
magnetite core with an average diameter of about 13 nm. To characterize the size of the 
magnetic core of the nanoparticles, transmission electron microscopy (TEM) was used 
(figure 3.3); the average diameter was found to be 13.4 nm  ±1.4 nm.  
Dynamic light scattering (DLS) was used to measure the hydrodynamic diameter 
of the nanoparticles after functionalization with the polymer and the heparin. The results 
showed the final particles increase in the hydrodynamic diameter after every step, to 
reach an average of 178.9 nm ± 2.2 nm for the first set and 137.1 ± 1.995 nm for the 
second set (table 3.1).  
Dimethylmethylene blue (DMMB) assay was used to quantify the heparin loading 
onto the nanoparticles using optical absorbance (21). Heparin loading was calculated to 
be 0.833 ± 0.010 µg heparin/µg nanoparticles for the first set and 0.311 ± 0.015 µg 
heparin/µg nanoparticles (figure 3.4).  
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Figure 3.4: Heparin loading quantified via optical absorption using DMMB 
assay and normalized to raw heparin. Top (set 1) and bottom (set 2). 
 
Table 3.1: Size characterization of the nanoparticles using DLS after synthesis and 
functionalization. Particle size increased with heparin functionalization. 
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Discussion: 
The use of heparin in vivo as an anticoagulant has been successful for years. 
While its antiproliferative effects on smooth muscle cells have long been shown in the 
literature (14, 26, 27), the required heparin concentrations to achieve this effect in vivo 
were much higher than those fitting in the therapeutic window of heparin when delivered 
systemically (10-16). In this chapter, a novel method of using heparin-coated magnetic 
nanoparticles is investigated for the potential delivery of heparin to sites of vascular 
injury that may alleviate some of these systemic side effects. Low molecular weight 
heparin (LMWH) was chosen over regular heparin because of its longer half-life and 
reduced side effects (18, 28, 29). 
The core particle size was chosen because particles with diameters less than 10 
nm have been shown to be filtered quickly by the kidneys and the liver filters particles 
with diameters larger than 30 nm (24, 25). The core diameter of the first set of particles 
was measured to be 13.4 nm and for the second set it was reported to be about 10 nm. 
The hydrodynamic diameter measured by DLS showed a difference in the diameters of 
the two sets. That is attributed to the length of the PEO used as a spacer for the first set.  
For heparin loading, the first set had more than twice the loading of the second 
set. The large polymer spacer allows for more negatively-charged heparin molecules to 
attach to the amine ends. However, the heparin loading on the second set is considered 
acceptable compared to the concentration needed to achieve the desired cell response. 
 
 
 
48 
 
Conclusions: 
We were successfully able to synthesize heparin-coated magnetic nanoparticles 
and achieve high heparin loading, both by synthesizing and modifying purchased 
nanoparticles. To improve the yield and heparin loading from the preliminary results, the 
nanoparticle synthesis process needs to be optimized. 
References: 
1. Kempe H, Kempe M. The use of magnetite nanoparticles for implant-assisted magnetic 
drug targeting in thrombolytic therapy. Biomaterials. 2010;31(36):9499-510. 
2. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 
2009;86(3):215-23. 
3. Chorny M, Fishbein I, Yellen BB, Alferiev IS, Bakay M, Ganta S, et al. Targeting 
stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform 
fields. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8346-51. 
4. Kempe H, Kempe M. The use of magnetite nanoparticles for implant-assisted magnetic 
drug targeting in thrombolytic therapy. Biomaterials. 2010;31(36):9499-510. 
5. Forbes ZG, Halverson DS, Fridman G, Yellen BB, Chorny M, Friedman G, et al. 
Locally targeted drug delivery to magnetic stents for therapeutic applications. Computer 
Architectures for Machine Perception, 2003 IEEE International Workshop on; IEEE; 
2003. 
 
49 
 
6. Räthel T, Mannell H, Pircher J, Gleich B, Pohl U, Krötz F. Magnetic stents retain 
nanoparticle-bound antirestenotic drugs transported by lipid microbubbles. Pharm Res. 
2012;29(5):1295-307. 
7. Lee JM, Park J, Kang J, Jeon K, Jung J, Lee SE, et al. Comparison among drug-eluting 
balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent 
restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC: 
Cardiovascular Interventions. 2015;8(3):382-94. 
8. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L. Long-
term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J 
Med. 2007;356(10):1009-19. 
9. Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- and gene-eluting stents for the 
prevention and treatment of coronary restenosis. Theranostics. 2014 Jan 8;4(2):175-200. 
10. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology 
of atherosclerosis and restenosis. Am J Cardiol. 2000;86(4):6H-11H. 
11. Rensen S, Doevendans P, Van Eys G. Regulation and characteristics of vascular 
smooth muscle cell phenotypic diversity. Netherlands Heart Journal. 2007;15(3):100-8. 
12. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell 
proliferation in injured arteries. Nature. 1977;265(5595):625-6. 
 
50 
 
13. Carey DJ. Control of growth and differentiation of vascular cells by extracellular 
matrix proteins. Annu Rev Physiol. 1991;53(1):161-77. 
14. Castellot JJ, Cochran DL, Karnovsky MJ. Effect of heparin on vascular smooth 
muscle cells. I. Cell metabolism. J Cell Physiol. 1985;124(1):21-8. 
15. Vadiveloo PK, Filonzi EL, Stanton HR, Hamilton JA. G1 phase arrest of human 
smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and 
cdk2. Atherosclerosis. 1997;133(1):61-9. 
16. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in 
restenosis. Circ Cardiovasc Interv. 2011 Feb 1;4(1):104-11. 
17. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. IV. 
Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res. 1986 
Jun;58(6):839-45. 
18. Gu Z, Rolfe BE, Thomas AC, Campbell JH, Lu GM, Xu ZP. Cellular trafficking of 
low molecular weight heparin incorporated in layered double hydroxide nanoparticles in 
rat vascular smooth muscle cells. Biomaterials. 2011;32(29):7234-40. 
19. Stone R, Fellows B, Qi B, Trebatoski D, Jenkins B, Raval Y, et al. Highly stable 
multi-anchored magnetic nanoparticles for optical imaging within biofilms. J Colloid 
Interface Sci. 2015;459:175-82. 
 
51 
 
20. Saville SL, Woodward RC, House MJ, Tokarev A, Hammers J, Qi B, et al. The effect 
of magnetically induced linear aggregates on proton transverse relaxation rates of 
aqueous suspensions of polymer coated magnetic nanoparticles. Nanoscale. 
2013;5(5):2152-63. 
21. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of 
sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochimica et 
Biophysica Acta (BBA)-General Subjects. 1986;883(2):173-7. 
22. Cullity BD, Graham CD. Introduction to magnetic materials. John Wiley & Sons; 
2011. 
23. Benz M. Superparamagnetism: theory and applications. Discussion. 2012. 
24. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. small. 2008;4(1):26-
49. 
25. Cheng F, Su C, Yang Y, Yeh C, Tsai C, Wu C, et al. Characterization of aqueous 
dispersions of Fe 3 O 4 nanoparticles and their biomedical applications. Biomaterials. 
2005;26(7):729-38. 
26. Pukac LA, Castellot JJ,Jr, Wright TC,Jr, Caleb BL, Karnovsky MJ. Heparin inhibits 
c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul. 1990 
Apr;1(5):435-43. 
 
52 
 
27. Gilotti AC, Nimlamool W, Pugh R, Slee JB, Barthol TC, Miller EA, et al. Heparin 
Responses in Vascular Smooth Muscle Cells Involve cGMP‐Dependent Protein Kinase 
(PKG). J Cell Physiol. 2014;229(12):2142-52. 
28. Fellows BD, Ghobrial N, Mappus E, Hargett A, Bolding M, Dean D, et al. In vitro 
studies of heparin-coated magnetic nanoparticles for use in the treatment of neointimal 
hyperplasia. Nanomedicine. 2018 Mar 8;14(4):1191-200. 
29. Gunn J, Cumberland D. Stent coatings and local drug delivery; state of the art. Eur 
Heart J. 1999 Dec;20(23):1693-700. 
  
 
 
 
 
 
 
 
 
 
 
53 
 
CHAPTER 4 
AIM 1.2: IN VITRO STUDIES 
Introduction:  
After injury, VSMCs have a shift towards a proliferative phenotype and enter the 
cell cycle (1). Synthetic VSMCs show a higher rate of migration and proliferation (1). 
The expression of contractile proteins is reduced and extracellular matrix components are 
produced (1). These changes contribute to the thickening of the intima media. Although 
restenosis is caused predominantly by the proliferation and migration of VSMCs, the 
roles played by endothelial cells and fibroblasts cannot be ignored. Endothelial cells in 
the tunica intima act as a selectively permeable barrier to prevent contact between 
VSMCs and growth factors circulating in the blood (2). Consequently, the endothelial 
layer inhibits intimal hyperplasia (2). Contrary to endothelial cells, fibroblasts role in 
restenosis is not well understood, however, recent studies have found that after injuries to 
the endothelial layer, myofibroblasts have been located in the adventitial layer (3). These 
fibroblasts have been found to express smooth muscle cell markers, such as smooth 
muscle actin and vimentin (3).  
We developed and tested novel heparin-coated magnetic nanoparticles to provide 
targeted delivery to the site of the stent, under an external magnetic field. In this chapter, 
we investigate the effect heparin-coated magnetic nanoparticles have on the viability and 
proliferation of human vascular cells in vitro.  
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Materials and Methods:  
Cell Culture: Vascular human cells were cultured in standard conditions, using the 
necessary cell culture media for each cell line. For these studies, human aortic smooth 
muscle cells (hAoSMC), human umbilical vein endothelial cells (hUVEC), and human 
dermal fibroblasts (hDF) were used. Recommended cell culture growth media (Cell 
Applications, INC, 311-500, 211-500, and 116-500) was used for each cell line.  
Uptake: To assess the cell uptake of the nanoparticles, TEM was used on 
hUVECs. Cells were seeded at 200,000 cells/ flask in two T75 flasks. One flask was 
treated with cell culture media with heparin coated nanoparticles at a 200 µg/mL 
concentration and the other with cell culture media as a control. Cells were incubated in 
standard conditions for 72 hours. After a three-day incubation, the cells were trypsinized 
and centrifuged to form a pellet. The pellet was fixed with 3% glutaraldehyde, osmified 
using 1% osmium tetroxide, dehydrated in a series of ethanol, and then infiltrated and 
embedded in LR White (4). Ultrathin sections (70-90 nm) were cut using a microtome 
and mounted on Formvar coated copper grids. A Hitachi H7600 TEM at 100kV was used 
for imaging. EDX was used to confirm the presence of iron inside the cells.  
Viability: The viability of each cell line was assessed using a live/dead assay to 
get both quantitative and qualitative results. Cells were plated in a 24-well plate with 
12,000 cells/well and incubated in cell culture media for 24 hours. After cell attachment, 
media was aspirated and nanoparticles at different concentrations were added to each 
well in quadruplicates and allowed to incubate for 72 hours, with cell culture media being 
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used as a control. After incubation, nanoparticle/media solutions were aspirated, cells 
were washed 3 times with Phosphate Buffered Saline (PBS), then a solution of Live/Dead 
assay using ethidium homodimer-1 (EtD-1) and calcein AM (Invitrogen) was added to 
each well. The solution was made with 1 µL/mL EtD-1 in PBS and 0.25 µL/mL calcein 
in PBS. A positive control with only EtD-1 or calcein was also prepared. Florescence was 
measured at 485 nm emission and 530 excitation, using a microplate reader, for 
quantitative results. The (% Live cells) was calculated according to the manufacturer’s 
protocol and normalized to the control. Light imaging using an EVOS FL microscope 
was used to assess the viability qualitatively.  
Proliferation: Proliferation studies were done on all three cell lines using MTS 
assay to compare the proliferation of the cells at different nanoparticle concentrations to 
nanoparticle-free controls. The MTS tetrazolium compound, [3-(4,5-dimethylthiazol-2-
yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], reacts with live, 
attached cells to form a colored product, formazan. Cells were plated in a 24-well plate 
with 12,000 cells/well and incubated in cell culture media for 24 hours. After cell 
attachment, media was aspirated and nanoparticles at different concentrations were added 
to each well in quadruplicates and allowed to incubate for 72 hours, with cell culture 
media being used as a control. hAoSMCs were treated with TGF-β for 24 hours, before 
treatment with the nanoparticles. After incubation, nanoparticle/media solution was 
aspirated, cells were washed three times with PBS, and MTS assay solution was added to 
each well at 1mL/well. The solution was prepared by mixing CellTiter Aqueous One 
Solution Cell Proliferation Assay (Promega) with cell culture media in a 1:5 ratio. The 
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cells were incubated for 4 hours with the MTS solution at 370 C, then triplicates of 180 
µL from each well were transferred to a 96-well plate, giving nine replicates of each 
treatment. Absorbance was measured at 490 nm using a microplate reader. Percent 
proliferation was calculated and normalized to the control.  
Gene Expression: Real-time polymerase chain reaction (qRT-PCR) was used to 
assess the effect of the nanoparticles on the phenotype of the hAoSMCs. Cells were 
treated with TGF-β for 24 hours before treatment with the nanoparticles. Cells were 
seeded at 200,000 cells/ flask in two T75 flasks. One flask was treated with cell culture 
media with heparin-coated nanoparticles at a 50 µg/mL concentration and the other with 
cell culture media as a control. Cells were incubated in standard conditions for 72 hours. 
Total RNA was collected from cells using TRIzol Reagent (Invitrogen). RNA 
purification was carried out per the manufacturer’s instructions. Single-stranded cDNA 
was obtained using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) following the manufacturer’s protocol. cDNA was then amplified in PCR 
using PowerUp SYBR Green Master Mix (Applied Biosystems) and specific primers 
(Integrated DNA Technologies). Amplification was performed using a StepOnePlus 
Real-Time PCR System (Applied Biosystems) with appropriate settings based upon the 
SYBR Green protocol. In hAoSMCs gene markers for smooth muscle 22 alpha (SM-
22α), calponin, and collagen type I were checked for changes in expression. 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) was used as a reference gene.   
Immunofluorescence: hAoSMCs were plated in a 6-well plate with 50,000 
cells/well and incubated in cell culture media for one day. Cells were treated with TGF-β 
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for 24 hours before treatment with the nanoparticles. Media was aspirated and 
nanoparticles at 50 µg/mL added to half the wells with cell culture media used as a 
control on the other half and allowed to incubate for 72 hours. After incubation, media 
was aspirated and cells were washed with PBS three times. Cells were fixed with a 4% 
formaldehyde (Sigma), 0.1% glutaraldehyde (Polysciences, Inc.) solution at room 
temperature for 20 minutes. Cells were permeabilized with a 0.1% Triton X-100 (Sigma) 
solution at room temperature for 15 minutes then blocked with a 2% blocking solution 
with 3% goat serum for 30 minutes at room temperature. A primary mouse antibody for 
alpha smooth muscle actin (Invitrogen, MA5-11547) at 1:500 ratio was added then 
allowed to incubate overnight in the fridge. Alexa Fluor 488 secondary antibody (Thermo 
Fisher Scientific) solution at 4 µL/mL was added for two hours at room temperature. 
Alexa Fluor 568 Phalloidin (Thermo Fisher Scientific) was added at a concentration of 
2.5% in PBS for 20 minutes at room temperature to stain for the actin cytoskeleton of the 
cell. 300 nM DAPI (4′,6-diamidino-2-phenylindole, Thermo Fisher Scientific) was added 
for 5 minutes at room temperature to stain for cell nuclei. Cells were rinsed three times 
with 1X PBS (Alfa Aesar) between every solution change. Cells were imaged using an 
EVOS FL light microscope at low and high magnifications. 
Statistical Analysis: An analysis of variance (ANOVA) with α=0.05 for random 
effects was performed for proliferation and cell viability to compare the effect of the 
different concentrations of nanoparticles on the cells. Dunnett’s post hoc test was used to 
compare the different treated groups to the control. A student t-test with α=0.1 was used 
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to compare the experimental group to the control for the PCR data, for each gene 
investigated. 
Results: 
Uptake: TEM was used to assess the uptake of the nanoparticles by hUVECs. 
Changes in the morphology of the cell membrane show that the particles are likely 
uptaken by the cells by pinocytosis and are internalized in endosomes inside the cells, in 
addition to being in the cytoplasm. EDX was performed on both control and experimental 
samples to compare the results. Iron peaks were seen in the treated sample, while none 
were detected in the control, confirming the presence of iron (figure 4.1). 
 
Figure 4.1:  TEM images showing the uptake of nanoparticles of hUVECs (scale bar = 2 
µm) and EDX showing the presence of iron. Top: Control, Bottom: 200µg/mL nanoparticle. 
Nanoparticles were observed in endosomes in the cells of the treated group and EDX 
confirmed the presence of iron in those samples. 
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Viability: Quantitative viability results (figure 4.2), normalized to the control, show no 
statistically significant difference between the viability of the cells treated with the 
nanoparticles and the control in any of the cell lines tested at any nanoparticle 
concentrations. None of the reductions exceeded 10% of that of the control. Qualitative 
results (figure 4.2) confirm the results calculated quantitatively. The images show a 
majority of green with very few cells stained red.  
 Proliferation: The effects of the nanoparticles on the proliferation of the different 
cell lines was analyzed after a 72-hour incubation using MTS. The results (figure 4.3) 
show an increase in the proliferation of hUVECs compared to the control that is 
statistically significant at most concentrations and a statistically significant reduction of 
at least 12% in the proliferation of the hAoSMCs compared to the control at all 
concentrations. There was no statistically significant change in the proliferation of hDFs 
at lower concentrations and a slight reduction at higher concentrations. These results 
confirm a suppression in the proliferation of smooth muscle cells after treatment with the 
nanoparticles even at concentrations as low as 10 µg/mL. 
Gene Expression: Gene expression was assessed using qRT-PCR. (figure 4.4) The 
expression of SM 22a was higher (P<0.1) in the treated cells compared to the control. 
The expression of calponin was increased in the treated cells and the expression of 
collagen was reduced.  
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Figure 4.2: Live-dead imaging and quantification of results assessing viability of 
different cells at different concentrations of nanoparticles. Scale Bar = 2000 um.  
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Figure 4.3: MTS assay results assessing cell proliferation at different 
concentrations of nanoparticles. Nanoparticle treatment increased HUVEC 
proliferation while it decreased hAoSMC proliferation. (ANOVA: α=0.05) 
Figure 4.4: qRT-PCR data showing expression of three genes 
compared in the control and nanoparticle treated hAoSMC.  
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Immunofluorescence: Immunofluorescence was used to visualize the changes in 
the morphology of hAoSMCs and the changes in marker expression compared to the 
control (figure 4.5). Changes in the morphology were noticed between the control and 
treated groups at low and high magnifications. (Figure 4C). In addition, there was a 
marked increase in the alpha smooth muscle actin staining (green) in the treated groups 
compared to the control. 
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Figure 4.5: Immunofluorescence images at low and high magnifications of 
representative hAoSMCs in control and 50µg/ml nanoparticle conditions. The top 
row shows the synthetic phenotype and the bottom shows the contractile phenotype 
after treatment with nanoparticles at low magnification (scale bar = 400um) and 
high magnification (scale bar = 100um). Red=actin filaments. Green=alpha smooth 
muscle actin. Blue=DAPI. Treated cells showed more alpha smooth muscle actin 
(green) staining. 
 
63 
 
Discussion:  
The uptake results agree with the results seen by Gu et al. (5) that showed 
LMWH-carrying particles and raw LMWH being uptaken to endosomes with pinocytosis 
in rat vascular smooth muscle cells. They show that LMWH-carrying particles, however, 
were able to escape from the endosomes, which prevents the degradation of heparin by 
lysosomes. The use of heparin in vivo as an anticoagulant has been successful for years. 
While its antiproliferative effects on smooth muscle cells have long been shown in the 
literature (6-8), the required heparin concentrations to achieve this effect in vivo were 
much higher than those fitting in the therapeutic window of heparin when delivered 
systemically (2, 6, 9-13). Previous studies by our group compared the effect of heparin-
coated magnetic nanoparticles produced by different methods to raw heparin. These 
showed that the nanoparticles were significantly more efficient at reducing the 
proliferation of smooth muscle cells than the raw heparin (14).  
The current nanoparticle design improves on these results as these particles have 
significantly less adverse toxicity effects in-vitro than the previous design. The results 
presented here show that the heparin nanoparticles are non-toxic to cells in vitro at 
concentrations as high as 200 µg/mL. The nanoparticles reduced the proliferation of the 
smooth muscle cells at concentrations as low as 10 µg/mL, corresponding to 83.3 µg 
heparin/mL. This heparin concentration is comparable to the ranges seen in systemic 
delivery in previous studies (2, 6, 9-13). The proliferation of hDFs was not changed at 
lower concentrations and was reduced slightly at higher concentrations, which is 
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consistent to the results seen by Castellot et al. (6) using raw heparin at similar 
concentrations.  
Our results indicate that there is a change in the phenotype of the smooth muscle 
cells. Vascular smooth muscle cell phenotypic shift between contractile and to synthetic 
phenotypes is on a scale rather than a binary change (10). In our study, cells were treated 
with TGF-β prior to the start of treatment. TGF-β induces the hAoSMC towards a more 
proliferative synthetic phenotype in vitro, which is similar to the phenotype of the cells in 
an injured or disease in vivo environment (15). Following nanoparticle treatment, these 
more synthetic hAoSMC cells seem to be shifting to more contractile-like phenotypes as 
was visualized using immunofluorescence and confirmed by PCR. Treated cells had a 
more spindle shape with organized aligned fibers that is associated with the contractile 
phenotype (figure 4.5), while the control cells were rhomboid in shape with randomly 
oriented fibers. A higher staining of alpha smooth muscle actin was also seen in the 
treated cells. While not all the changes in the gene expression were statistically 
significant, they showed a trend in the contractile phenotype direction. Taken together 
with the proliferation assay results, this suggests that heparin-coated iron oxide 
nanoparticles could have promise for the treatment of vascular injury or disease as they 
increase endothelial cell proliferation while keeping vascular smooth muscle cells in a 
less proliferative more contractile-like phenotype.  
The concentrations of nanoparticles tested here fall in the range that has been used 
by others investigating magnetic nanoparticle targeting to stents. These prior studies have 
found that concentrations around 50 µg/mL are relevant to in vivo particle capture with 
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magnetic fields. For instance, Aviles et al. achieved a capture efficiency of 50% ex vivo 
using a concentration of 50 µg/mL with a fluid velocity of 42.4 cm/s and a magnetic field 
of 0.65 T (16). Chorny et al. had a 4.4% capture efficiency in vivo, in the arterial tissue, 
using a particle concentration of 20 µg/mL of paclitaxel-loaded particles (17).  
Endothelial cells have been shown to reduce the proliferation of smooth cells and 
fibroblasts change their phenotype to myofibroblasts when the adjacent smooth muscle 
cells are completely synthetic. The studies shown in this chapter show that for future 
studies, nanoparticle concentration < 50 µg/mL could be safely and effectively used.  
Conclusions:  
The synthesized nanoparticles are nontoxic to cells and reduce the proliferation 
and dedifferentiation of vascular smooth muscle cells while promoting endothelialization, 
which is consistent with the results of delivering heparin systemically. Nanoparticle 
concentrations of < 50 µg/mL are relevant for further in vivo investigations. These 
particles show promise as a localized treatment of neointimal hyperplasia which is turn 
leads to the prevention of restenosis without the side effects associated with the current 
treatments.  
References: 
1. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell 
differentiation. Journal of vascular surgery. 2007;45(6):A25-32. 
2. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in 
restenosis. Circ Cardiovasc Interv. 2011 Feb 1;4(1):104-11. 
 
66 
 
3. Strauss BH, Rabinovitch M. Adventitial fibroblasts: defining a role in vessel wall 
remodeling. American journal of respiratory cell and molecular biology. 2000;22(1):1-3. 
4. Ng C, Li J, Perumalsamy R, Watt F, Yung L, Bay B. Localizing cellular uptake of 
nanomaterials in vitro by transmission electron microscopy. 
Microsc.Sci.Technol.Appl.Educ. 2010;1:316-20. 
5. Gu Z, Rolfe BE, Thomas AC, Campbell JH, Lu GM, Xu ZP. Cellular trafficking of 
low molecular weight heparin incorporated in layered double hydroxide nanoparticles in 
rat vascular smooth muscle cells. Biomaterials. 2011;32(29):7234-40. 
6. Castellot JJ, Cochran DL, Karnovsky MJ. Effect of heparin on vascular smooth muscle 
cells. I. Cell metabolism. J Cell Physiol. 1985;124(1):21-8. 
7. Pukac LA, Castellot JJ,Jr, Wright TC,Jr, Caleb BL, Karnovsky MJ. Heparin inhibits c-
fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul. 1990 
Apr;1(5):435-43. 
8. Gilotti AC, Nimlamool W, Pugh R, Slee JB, Barthol TC, Miller EA, et al. Heparin 
Responses in Vascular Smooth Muscle Cells Involve cGMP‐Dependent Protein Kinase 
(PKG). J Cell Physiol. 2014;229(12):2142-52. 
9. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of 
atherosclerosis and restenosis. Am J Cardiol. 2000;86(4):6H-11H. 
 
67 
 
10. Rensen S, Doevendans P, Van Eys G. Regulation and characteristics of vascular 
smooth muscle cell phenotypic diversity. Netherlands Heart Journal. 2007;15(3):100-8. 
11. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell 
proliferation in injured arteries. Nature. 1977;265(5595):625-6. 
12. Carey DJ. Control of growth and differentiation of vascular cells by extracellular 
matrix proteins. Annu Rev Physiol. 1991;53(1):161-77. 
13. Vadiveloo PK, Filonzi EL, Stanton HR, Hamilton JA. G1 phase arrest of human 
smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and 
cdk2. Atherosclerosis. 1997;133(1):61-9. 
14. Fellows BD, Ghobrial N, Mappus E, Hargett A, Bolding M, Dean D, et al. In vitro 
studies of heparin-coated magnetic nanoparticles for use in the treatment of neointimal 
hyperplasia. Nanomedicine. 2018 Mar 8;14(4):1191-200. 
15. Guo X, Chen SY. Transforming growth factor-beta and smooth muscle 
differentiation. World J Biol Chem. 2012 Mar 26;3(3):41-52. 
16. Aviles MO, Chen H, Ebner AD, Rosengart AJ, Kaminski MD, Ritter JA. In vitro 
study of ferromagnetic stents for implant assisted-magnetic drug targeting. J Magn Magn 
Mater. 2007;311(1):306-11. 
 
68 
 
17. Chorny M, Fishbein I, Yellen BB, Alferiev IS, Bakay M, Ganta S, et al. Targeting 
stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform 
fields. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8346-51. 
  
 
69 
 
CHAPTER 5 
AIM 2: COMPUTATIONAL MODELING 
Introduction: 
Historically, in vitro and in vivo studies were the only available options to 
evaluate the safety and effectiveness of our drug delivery system. Recently, the use of 
computational models has increased in evaluating drugs and medical devices, due to their 
ability to provide faster, cheaper, accurate, and patient specific results. Theoretical and 
computational models allow us to control multiple factors and offer a supplementary look 
at the different designs and their success. Models of blood vessels also provide a detailed 
look at the mechanical interactions including blood flow mechanics, velocity, and shear 
stress and how they affect the endothelium and the vascular smooth muscle cells in the 
medial layer.  
To fully understand the dynamics of the magnetic field with the nanoparticles, 
stent, blood flow, and the stented artery, we used a computational model to simulate the 
interactions between the different components of our system. This model allowed us to 
test different assumptions and evaluate the efficacy of our drug delivery system. It also 
allowed us to examine different options for stent materials and strut geometries, to be 
able to select the ideal stent for our system. 
Materials and Methods: 
Geometry: The fluid dynamics, magnetic field, and particle tracing for fluid flow 
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packages of COMSOL Multiphysics were utilized to create a 2D axisymmetric model of 
a stented artery. The use of a 2D model rather than a 3D version reduced the 
computational cost of each simulation. The artery was modeled as a channel with a radius 
of 3 mm and a height of 250 mm (1). The vascular wall is composed of intima, media, 
and adventitia layers of thicknesses 0.230 mm, 0.306 mm, and 0.340 mm, respectively (2, 
3). The arterial wall has a Young’s modulus of 3x108 Pa and a Poisson’s ratio of 0.27 (4). 
The model geometry is shown in figure 5.1. 
 
Geometry descriptions were classified by the geometric shape of an individual 
strut (figure 5.2). Two models included rectangular stent geometries and the third model 
included a circular arc geometry. The rectangular models differed through varying aspect 
ratios (AR) of width to height, w:h, where one model had an AR equal to 6:1 (R6:1) the 
Figure 5.1: The design of the 2D axisymmetric model of a stented artery. 
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other had an AR equal to 3:1 (R3:1). The circular stent geometry had an AR of 6:1 
(A6:1). Each model included six struts of equal strut height, 0.2 mm, and distance 
between each strut, 0.2 mm (2). 
Hemodynamics: The flow in the channel was treated as Newtonian and 
incompressible and modeled by solving the Navier-Stokes equations. The blood inlet 
velocity profile (𝑢𝑢(𝑟𝑟, 𝑡𝑡)) is defined by the following equation (5): 
𝑢𝑢(𝑟𝑟, 𝑡𝑡) =
1.525𝜌𝜌
4𝜇𝜇
�(cos(2𝜋𝜋𝑡𝑡) + 1.55)��
𝐷𝐷
2�
2
− 𝑟𝑟2�� 
R6:1                     R3:1                   A6:1  
Figure 5.2: The different stent strut geometry tested. The stented artery 
geometry of) rectangular 3:1, rectangular 6:1, and circular arc 6:1, including 
both the arterial model and single stent strut. 
w  
h  
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where the blood density, ρ, dynamic viscosity, μ, are 1060 kg/m3 and 4x10-3 Pa•s, 
respectively (2). D is the cavity diameter, t is time and r is the radial spatial coordinate. 
The pulsatile flow model was preferred over a steady flow model, as it more accurately 
depicts the pulsatile nature of blood flow. Additionally, the cavity wall was given a roller 
boundary condition to allow for arterial wall movement. This wall motion gains 
additional legitimacy from the properties of the three arterial layers to the model (2, 3). 
Blood was assumed to be a homogeneous continuum. This assumption is valid in 
medium and large sized blood vessels, because they have diameters much larger than that 
of a red blood cell, so the blood seems homogeneous (6). 
Magnetic properties: The magnetization of the stent was modeled as (7): 
𝐵𝐵�⃑ = 𝜇𝜇0𝜇𝜇𝑟𝑟 ,𝑠𝑠𝐻𝐻�⃑  
where 𝐵𝐵�⃑  is the magnetic flux density, 𝐻𝐻�⃑  is the magnetic field, 𝜇𝜇0 is the 
permeability of the vacuum (4𝜋𝜋 x10-7 N/A2), and 𝜇𝜇𝑟𝑟,𝑝𝑝 is the relative permeability of the 
stent. 𝐻𝐻�⃑  was calculated to be 442,097.0641 A/m and the stent was given a relative 
permeability of 1.8, which resembles that of 304 grade stainless steel (4). The relative 
permeability of the particles (µr,p) was modeled to be 100 and they had a radius of 7 nm 
(8).  
The magnetic force acting on a single nanoparticle (?⃑?𝐹𝑚𝑚𝑚𝑚𝑚𝑚) was modeled using the 
following equation (7): 
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?⃑?𝐹𝑚𝑚𝑚𝑚𝑚𝑚 =
4𝜋𝜋𝑟𝑟𝑝𝑝3
3
𝜇𝜇0𝜒𝜒
(1+𝜒𝜒3)
�𝜕𝜕𝐻𝐻�⃑
𝜕𝜕𝑟𝑟
�
𝑇𝑇
= 2𝜋𝜋𝑟𝑟𝑝𝑝
3
3
𝜇𝜇0𝜒𝜒
(1+𝜒𝜒3)
 ∇ ��𝐻𝐻�⃑ �
2
� 
where rp is the radius of the particle, 𝑟𝑟 is the position of the particle and 𝜒𝜒 is the 
magnetic susceptibility.  
Other forces acting on the particles: Brownian motion and drag force were 
considered as the significant, non-magnetic forces acting on the particles. The 
gravitational force and buoyancy force on the particles were ignored due to their 
insignificant order of magnitude compared with the previously mentioned forces (9, 10). 
The Brownian force on the particles (FB) is defined by the equation (10):  
FB = δ√2𝐶𝐶𝐶𝐶𝑇𝑇√𝑑𝑑𝑑𝑑    , where C = 6πμrp 
where δ is the stochasic variable, k is Boltzmann’s constant ,1.38 × 10-23 N•m•K-1 
and T is the absolute temperature in K. The drag force (FD) on the particle is given by 
(11): 
FD = 𝐶𝐶(𝑢𝑢 − 𝑣𝑣) 
where v is the particle velocity. Lift inertial force and particle-particle interactions 
were tested in the model and did not influence the particle capture; therefore, they were 
neglected to reduce computational cost. Lift inertial force was modeled as (12): 
𝐹𝐹𝐿𝐿 =
𝐶𝐶𝐿𝐿𝐷𝐷ℎ2
𝜌𝜌𝑣𝑣2𝑟𝑟𝑝𝑝4
 
where 𝐶𝐶𝐿𝐿 is the lift coefficient and 𝐷𝐷ℎ2 is the hydraulic diameter.  
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Particle-particle interactions were modeled using Coulomb’s Force. It was 
assumed that the polymer and heparin coating on the nanoparticles do not affect the 
particle-particle interactions. The addition of PEO of a molecular weight of at least 5000 
g/mol has been shown to increase colloidal stability of the nanoparticles and reduce 
particle aggregation (13). Heparin’s negative charge also plays a role in preventing 
particle aggregation by increasing electrostatic repulsion (14, 15) 
Model parameters: The model was meshed using tetrahedral elements. Corner 
refinement was applied and a three-layer boundary was built along the arterial lining. The 
final mesh had a maximum element quality of 0.00133, a minimum of 7.5*10-6, a 
maximum element growth rate of 1.3, and a curvature factor of 0.3. 100 nanoparticles 
were released simultaneously from the artery inlet with a density corresponding to flow 
velocity and under an identical flow velocity field and external magnetic field conditions.  
For computational ease, a freeze boundary condition was applied to the arterial 
wall and stent struts to capture the nanoparticle after first contact. Capture efficiency 
(CE) was determined by calculating the number of particles that were frozen to the 
arterial wall or stent struts per total number of particles released. The blood velocity, 
shear stress, and magnetic flux density around the stent struts were observed and their 
maximum and minimum values were analyzed.  
Model Validation: Shear stress was compared to the shear stress seen by Jimenez 
et al. (16) and capture efficiency was compared to the results seen by Wang et al. (4). The 
capture efficiency seen was also validated using ex vivo static and dynamic models, 
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where nanoparticles were delivered to porcine arteries. The results of the ex vivo analyses 
are shown in chapter 6.  
Results: 
Blood velocity, shear stress, and magnetic flux density were observed for each of 
the stent strut designs and their maximum and minimum values were calculated. The 
particle capture efficiency was also calculated for each of the strut designs. The capture 
efficiency for R1:6 was 34%, for R3:1 was 35%, and for A6:1 was 42%. The capture 
efficiency when 𝐻𝐻�⃑ =0 was 1%. 
The effect of the different stent strut geometries on the shear stress is shown in 
figure 5.3. Rectangular struts had a wider ranges of shear stress values than the arch one 
with R3:1 having the highest and the lowest values. It was observed, however, in figure 
5.3D, that the areas with the lowest shear stress are the tip of the strut not the arterial 
wall.   
The magnetic flux density around each of the stent strut geometries is shown in 
figure 5.4. As expected, the size of the strut had a larger effect on how it was magnetized 
than its geometry. R3:1 had the highest value with 1.85 T, while A6:1 had the lowest at 
1.67 T. Figure 5.4C shows that while R6:1 and A6:1 had similar values, they had 
different field distributions.  
Figure 5.5 shows the effect of the different stent strut geometries on the blood 
velocity. Rectangular struts were observed to have higher velocities than the arch one, 
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with R6:1 having the highest velocity at 2.267 m/s and A6:1 having the lowest velocity at 
1.828 m/s.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Shear stress for the different stent strut geometries (A) range of 
values, (B) maximum and minimum values, (C) contour showing 
distribution of values and streamline, (D) enlarged stent struts showing 
details of distribution and streamline. 
Strut R6:1 R3:1 A6:1
Max 62.7 63.3 65.2
Min 0 0 0
Shear Stress [Pa]
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Strut R6:1 R3:1 A6:1
Max 1.6656 1.8514 1.6655
Min 6.50E-08 6.49E-08 6.51E-08
Magnetic Flux Density [T]
Figure 5.4: Magnetic flux density for the different stent strut geometries 
(A) range of values, (B) maximum and minimum values, (C) contour 
showing areas with maximum and minimum values, (D) enlarged stent 
struts showing details of distribution. 
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Strut R6 R3 A6
Max 2.2672 2.2665 1.8182
Min 8.62E-07 4.12E-08 9.34E-07
Velocity [m/s]
Figure 5.6: Velocity for the different stent strut geometries (A) range of 
values, (B) maximum and minimum values, (C) contour showing areas 
with maximum and minimum values, (D) enlarged stent struts showing 
details of distribution. 
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Discussion: 
Magnetically guided drug delivery systems offer a great tool for targeted drug 
delivery. Computational modeling facilitates accurately designing and testing the 
parameters needed for these systems. In this model, COMSOL Multiphysics was used to 
model the blood flow in a stented artery and calculate the capture of magnetic 
nanoparticles under an external magnetic field. Three different stent strut geometries 
were tested to optimize the parameters needed for this model.  
The capture efficiency of the different stent strut geometries was affected by the 
different variables in the model. Strut A6:1 had the highest capture efficiency at 42%. 
That value could mainly be attributed to the low velocity around this strut. The capture 
efficiency values are similar to the values modeled by Wang et al. (4) at the same particle 
radius. Their capture efficiency was 20-30% for rectangular stent struts. 
Many studies have shown the effect of shear stress on the healing of the 
endothelial layer and of neointimal hyperplasia (17-22).  Higher shear stress has been 
shown to promote adaptive dilatation and structural remodeling of the blood vessel, 
which is associated with less intimal thickening. Reductions in shear stress affect the 
signaling and gene expression of endothelial cells and vascular smooth muscle cells, 
which in turn adapt to shear stress by altering vessel architecture. Strut A6:1 was shown 
to have the ideal shear stress parameters among the tested struts. The shear stress results 
seen are comparable to Jimenez et al. (16). 
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The effect of the different strut geometries has not been previously evaluated. 
While the effect of the size of the strut has a larger effect on the magnetic flux density 
value, the geometry was observed to have an effect of the distribution. That could be 
attributed to Gauss’s Law for magnetism where: 
�𝐵𝐵.𝑑𝑑𝑑𝑑
.
𝑆𝑆
= 0 
where S is the closed surface and A is the area.  
Based on these results, strut A6:1 had the most desirable parameters among the 
tested designs. It had the highest capture efficiency with a slightly higher shear stress 
properties, which offers higher drug delivery and less damage to the vascular wall. 
Conclusions: 
The model shows that a circular arc geometry should be preferred for maximum 
capture efficiency over a rectangular geometry for stent strut design. When compared to 
the rectangular geometry of the same dimensions, the more streamlined circular arc stent 
created less hemodynamic disturbance and optimal shear stress, thus the magnetic forces 
localized by the stent struts were able to better act on the nanoparticles. This result 
indicates that a streamlined design is more consequential than a design which maximizes 
magnetic force through surface area, although when comparing stents of similar 
geometry, a larger area does increase capture efficiency as shown through the comparison 
of the rectangular stents.  
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CHAPTER 6 
AIM 3: EX VIVO STUDIES 
Introduction: 
Atherosclerosis is a cardiovascular disease caused by the buildup of plaque in 
arteries over years. Atherosclerosis is commonly found in coronary arteries and can cause 
myocardial infarctions, which may lead to death. A common treatment for atherosclerosis 
is the use of stents, which increase the patency of the blood vessel and provide 
mechanical support to the vascular wall (1, 2). The use of stents to treat atherosclerosis 
introduced new complications, mainly restenosis. Restenosis is caused by an injury to the 
vascular wall or a disturbance in the shear stress, due to the thickness of the stent struts 
(2-5). These factors directly lead to neointimal hyperplasia, which leads to restenosis, if 
left untreated (2).  
An injury to the vascular wall causes damage to the endothelial layer which leads 
to the proliferation of the vascular smooth muscle cells (VSMC) and their 
dedifferentiation from their contractile phenotype to a synthetic phenotype. These 
changes lead to the thickening of the medial layer of the vascular wall and to a reduction 
in the patency of the blood vessel. 
We designed a drug delivery system to treat neointimal hyperplasia using heparin-
coated magnetic nanoparticles delivered to a magnetizable stent under a magnetic field. 
In vitro studies (shown in chapter 4) showed a promise in reducing the proliferation and 
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dedifferentiation of VSMCs and increasing the differentiation of endothelial cells. Our 
computational model of the drug delivery system, shown in chapter 5, predicted a capture 
efficiency of 34-42%. 
To confirm the results seen in in vitro studies and computational modeling, we 
tested the drug delivery system ex vivo, on porcine coronary arteries. Ex vivo studies 
provide a more comprehensive look at the interactions between vascular cells and 
vascular wall response. Our ex vivo studies were performed both statically and 
dynamically. The dynamic studies were performed using a vascular bioreactor, to 
simulate hemodynamic conditions.  
Materials and Methods: 
Tissue preparation: Fresh porcine right coronary arteries (Animal Technologies, 
Inc.) were cleaned from excess fat, washed in PBS, and cultured in T25 flasks in DMEM 
with 15% FBS and 2% Ab-Am. Arteries were then incubated in 130 ng/mL TGF-β 
(Promo Kine) for seven days to induce neointimal hyperplasia (6). After incubation, the 
arteries were used in different conditions, shown in table 6.1. 
TGF-β studies: To show the effect of TGF-β on the response of the arteries to 
injury, arteries (n=3) were incubated in DMEM containing TGF-β for seven days. 
Control arteries were incubated in DMEM only. After seven days, injury to the arterial 
walls was induced using a needle, to simulate stent implantation. Arteries were incubated 
for 72 hours after injury then analyzed.  
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Static studies: After treatment with TGF-β, injury to the arterial walls was 
induced using a needle, to simulate stent implantation. Arteries continued to be incubated 
in T25 flasks. The experimental arteries (n=3) were incubated in nanoparticles (NP) at 50 
µg/mL in DMEM and the control arteries were incubated in DMEM only. After 72 hours, 
NP solution and DMEM were aspirated and changed to DMEM solution. A set of 
experimental arteries were collected to be analyzed and the control and other set of 
experimental arteries were incubated in DMEM for additional four days, before analysis.  
 
 
 
 
 
Dynamic studies: After incubation in diseased media, a bare metal stent (VeriFlex 
Monorail Coronary Stent, 12mm-20mm x 4.50mm, Boston Scientific) was inflated inside 
the artery (n=3-4). The ends of the arteries were attached to polymer barb x Luer fittings 
(polypropylene and polycarbonate) and tied using medical sutures, then connected to the 
bioreactor (Aptus Bioreactors, LLC, Clemson, SC; www.AptusBR.com). The fittings 
were attached to glass manifolds using dental SC polymer connectors (Form Labs) 
passing through the chamber walls and sealed with silicone o-rings. The system was 
Conditions Static Dynamic 
Control Cell culture flask 
CCM 
Bioreactor 
Stent 
CCM 
Experimental Cell culture flask 
NP Treatment 
Bioreactor 
Stent 
NP Treatment 
Table 6.1: The conditions of the static and dynamic experiments. 
NP=nanoparticle, CCM=cell culture media.  
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connected to a peristaltic pump at a flow rate of 50 mL/min/artery, which was then 
damped by a 250 mL dampening chamber before passing through a pinch valve set to an 
open time of 300 ms and a close time of 500 ms (75 BPM) to create the pressure and 
pulsatile flow. After passing through the vessels, a 250 mL compliance chamber and a 
series of adjustable constriction clamps were used to control the systolic and diastolic 
pressures which were 130-100 mmHg/ 60-30 mmHg. The media then flowed back 
through the chamber and around the outside of the vessels at near-zero pressures before 
passing through a media reservoir with a filtered cap (0.22 µm) for air exchange. Pressure 
transducers measured pressure inside and outside the vessels and flow meter were 
connected to the controls box which reported these values to the software. A schematic of 
the bioreactor is shown in figure 6.1 and a picture of the bioreactor setup and the user 
interface are shown in figure 6.2.   
Figure 6.1: A schematic of the arterial bioreactor setup. Vessels are shown 
connected in parallel in the middle of the chamber. Black arrow= NP injection. 
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The bioreactor was run three times: one control and two experimental. One 
experimental run went for five days, one experimental run was stopped after three days. 
For the experimental runs, N52 Grade 0.5 inch x 0.5 inch x 0.5 inch neodymium iron 
boron NdFeB cube magnets (Applied Magnets) were placed on the top and bottom of the 
bioreactor chamber and 50 µg/mL of nanoparticles were injected into the manifold 
leading into the arteries. DMEM with 15% FBS and 2% Ab-Am was used for all the 
bioreactor runs, under standard tissue culture conditions. After the incubation period, the 
arteries were collected for analysis.  
 
Tissue processing (static and TGF-β studies): The collected tissues were washed 
in PBS then fixed in 10% formalin. The fixed tissue was processed and embedded in 
parafin, then sectioned to 5 µm sections using a microtmome and mounted on glass 
slides. The slides were heated in the oven at 56oC for an hour. Before staining, the slides 
Figure 6.1: A schematic of the arterial bioreactor setup. Vessels are shown 
connected in parallel in the middle of the chamber.  
 
A 
Figure 6.2: (A) Arterial bioreactor setup, with magnets on top and bottom of 
chamber and during nanoparticles injection. (B) User interface for the 
bioreactor. 
B A 
A 
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were deparafinized with xylene.  
Tissue processing (dynamic studies): The collected tissues were washed in PBS 
then fixed in 10% formalin. The fixed tissue was processed and embedded in glycol 
methacrylate (GMA), to preserve the stent. After fixing, the tissue was processed in 
GMA for two weeks under vaccum, then embedded in GMA under ultravilot light for 24 
hours. The GMA blocks were cut into sections of ~5 mm in thickness using a band saw. 
The GMA sections were then glued to plexiglass slides then polished to ~80-120 µm 
sections using a grinding wheel.  
Histological staning: All the slides were dipped in graded ethanol before staining. 
Hematoxylin and eosin (H&E) stain was used to stain the nuclei blue to purple and 
cytoplasm and ECM pink to red. Masson’s trichrome was used to stain the nuclei black, 
cytoplasm, muscle fibers and intracellular fibers red, and collagen blue. All the 
histological stains were performed according to manufacturers’ protocols. 
Immunoflourescence: tissue slides were heated up in a sodium citrate buffer 
solution at 100oC for 20 minutes for antigen retrieval. After antigen retrieval, the tissues 
were permeabilized with a 0.1% Triton X-100 (Sigma) solution at room temperature for 
15 minutes then blocked with a 2% blocking solution with 3% goat serum for 30 minutes 
at room temperature. A primary antibody for alpha smooth muscle actinin (1E12 was 
deposited to the DSHB by Little, C.D. (DSHB Hybridoma Product 1E12)) or CD45 
(CD45 (K252.1E4): sc-59065, Santa Cruz Biotechnology, INC.) at 1:500 ratio was added 
then allowed to incubate overnight in the fridge. Alexa Fluor 568 secondary antibody 
(Thermo Fisher Scientific) solution at 4 µL/mL was added for two hours at room 
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temperature. Tissues were rinsed three times with 1X PBS (Alfa Aesar) between every 
solution change. Tissues were imaged using an EVOS FL light microscope. 
Uptake analysis: Pieces (0.5 mm x 0.5 mm x 0.5 mm) of each of the collected 
arteries were fixed in gluteraldhyde then frozen in saline. The frozen samples were 
digested in 37% hydrochloric acid (HCl) solution for one hour at 80oC then allowed to sit 
overnight (7). The HCl solution was evapourated and replaced with 3% nitic acid and 
sent to Clemson University Agricultural Service Laboratory to quatify the amount of iron 
found in the samples using Inductively Coupled Plasma (ICP). The iron oxide 
concentration was calculated from the amout of iron measured with ICP. The 
experimental samples were normalized to the control, then the capture efficincy was 
calculated. 
Statistical analysis: ICP data for uptake was compared with the controls using 
one-way ANOVA (α=0.05) for the static and dynamic samples separately. Tukeys’ post 
hoc test was used to analyze the difference between the groups. The static and dynamic 
groups were compared using randomized block design ANOVA (α=0.05).  
Results:  
TGF-β studies: The tissues treated with TGF- β were compared to the control. 
The tissues stained with H&E, shown in figure 6.3, show the morphological changes in 
the neointimal healing in the control compared to the diseased model. The images at high 
magnification (40X) show the effect of TGF-β on the nuclei in the medial layer, where 
the nuclei are randomly oriented and areas of thickening in the intimal layer are noticed. 
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Masson’s trichrome (figure 6.4) showed more prominent morphological changes to the 
vascular wall after treatment with TGF-β. More collagen deposition (shown in blue) is 
noticed in the TGF-β treated tissues.  
Immunofluorescent staining (figure 6.5) of the tissues shows a reduction in the 
expression of smooth muscle alpha actinin in the TGF-β treated tissues and an increase in 
the expression of CD45. The images also show morphological changes in the treated 
tissues including areas of wall thickening at low magnification and changes is the muscle 
fibers to a more random orientation after treatment.     
Static studies: Tissues treated with nanoparticles were compared to the control. 
H&E stained tissues, shown in figure 6.6, show the morphological changes in the 
neointimal healing in the treated groups compared to the control. Areas with neointimal 
thickening are noticed in the control tissues compared to the control. Masson’s trichrome 
(figure 6.7) showed more collagen deposition (shown in blue) in the control arteries 
compared to the treated tissue. Conversely, the nanoparticle-treated tissues show more 
muscle fibers, shown in red, in the medial layer, specially noticed at higher 
magnifications (40X). 
Immunofluorescent staining (figure 6.8) of the tissues shows an increase in the 
expression of smooth muscle alpha actinin in the nanoparticle treated tissues and a 
reduction in the expression of CD45 that is mostly limited to the injured regions.  
Dynamic studies: H&E staining (figure 6.9) for the three-day treated control 
shows uniform thickness in the vascular wall compared to the control. For Masson’s 
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trichrome (figure 6.10) stained arteries, the experimental arteries more muscle fibers (red) 
than the control arteries. For immunofluorescence (figure 6.11), tissues treated with 
nanoparticles for three days show higher expression of smooth muscle alpha actinin in 
the nanoparticle treated tissues and a reduction in the expression of CD45 compared to 
the control. Intimal thickening around and CD45 expression are also noticed in the 
control tissue stained for CD45. 
Uptake studies: The nanoparticles uptake results show that the particles are 
uptaken by the tissue. The tissues analyzed after three days show significantly higher 
amounts of internalized particles than the controls and the longer incubated tissues. For 
the static tissue, day three was significantly different from both the control and day seven. 
For the dynamic tissue, there was a statistically significant difference in the uptake 
between day three and the control. The uptake of the statically conditioned arteries was 
also significantly different from that of the dynamically conditioned ones. The capture 
efficiency of the static tissue was 18.8% at day three and 1.32% at day 7. For the dynamic 
tissue, the capture efficiency was 31.4% at day three and 3.70% at day five. 
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Discussion: 
This study analyzed the effect of heparin-coated magnetic nanoparticles on the 
formation of neointimal hyperplasia, ex vivo on porcine coronary arteries. The arteries 
were treated with TGF-β for 7 days before treatment to introduce a diseased model (6). 
Arteries treated with TGF-β were compared to control untreated arteries to ensure the 
effect of TGF-β on the arteries. Arteries treated with TGF-β showed regions of 
neointimal thickening, higher CD45 expression, lower smooth muscle actinin expression, 
and more collagen deposition than the control, indicating that the TGF-β treated arteries 
showed signs of neointimal hyperplasia.  
Figure 6.12: ICP data of the particle uptake by the arteries for the 
different incubation periods, both statically and dynamically. one-way 
ANOVA (α=0.05) 
*                             * 
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Healthy arteries express higher smooth muscle contractile markers, such as 
smooth muscle actin, smooth muscle actinin, and calponin (1, 2, 8-10). The medial layer, 
composed mostly of smooth muscle cells, has arranged muscle fibers that facilitate 
healthy blood flow. When and injury occurs, the smooth muscle cells dedifferentiate to a 
synthetic phenotype and proliferate, causing thickening in the vascular wall. Synthetic 
smooth muscle cells express less contractile proteins and produce collagen and ECM. 
CD45 is a cell surface protein found on leukocytes. It has been expressed in the arterial 
wall in acute local inflammation episodes and during angiogenesis (11-13).  
The arteries treated with nanoparticles showed less neointimal thickening than the 
controls and they had higher expression of smooth muscle actinin and more fibers in the 
medial layer than the control. The injured, nontreated arteries had thicker arterial walls 
with higher expression of CD45 and more collagen deposition in the medial layer.  
The dynamic arteries had less conclusive results, which could be attributed to the 
harsh processing procedure used for them. The GMA embedded tissues are glued to the 
slides and grinded using sand paper, which caused some damage to the tissue, seem 
clearly in the day 5 images.  
The nanoparticles were uptaken by the tissues under both conditions. The uptake 
was significantly higher at day three, which indicates that the particles are released by the 
tissue. This agrees with our previous results (appendix J) where 3T3 fibroblasts were 
treated with amine-terminated particles and their uptake was studied by TEM over a 
seven-day period. The cells started to release the nanoparticles at day four and fewer 
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particles were visualized after. This also agrees with in vivo results shown in Fellows et 
al. (14) where similar heparin-coated nanoparticles were injected systemically into mice 
and were all cleared very rapidly.  
The capture efficiency of the nanoparticles by the dynamically conditioned tissue 
at day three was in line with the capture efficiencies predicted by the computational 
model in chapter 5. The lower value could be attributed to the stent strut geometry and 
the computational model assumptions. 
Conclusion: 
Heparin-coated magnetic nanoparticles showed promise in the treatment of 
neointimal hyperplasia in an ex vivo porcine artery model. The particles reduced 
neointimal thickening at concentrations as low as 50 µg/mL within three days. They also 
increased the expression of the smooth muscle contractile gene expression in injured 
diseased arteries and reduced the inflammatory response that would lead to neointimal 
hyperplasia and eventually restenosis in this ex vivo model. The particle capture 
efficiency for the dynamic model was comparable to the computational model and most 
of the particles were released by the arteries within seven days.  
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
Atherosclerosis is a highly prevalent cardiovascular disease in the industrialized 
world. Stents have been used in the treatment of atherosclerosis for about 40 years. While 
having high success rates, stents introduced new complications, including neointimal 
hyperplasia that leads to restenosis. In response to this, we designed heparin-coated 
magnetic nanoparticles that could be delivered to a magnetizable stent. The designed 
nanoparticles showed promise in the treatment of neointimal hyperplasia. 
The nanoparticles were synthesized and characterized successfully. A set of 
nanoparticles was synthesized using thermal decomposition to synthesize a magnetite 
core, then modified with an amine terminated polymer, then modified with heparin. A set 
of amine-terminated magnetite nanoparticles was also acquired from a manufacturer and 
modified with heparin.  
The particles were tested in vitro on human cells. The particles were not toxic to 
any of the cell lines tested at concentrations as high as 200 µg/mL. They were able to 
increase the proliferation of endothelial cells and reduce the proliferation of smooth 
muscle cells. The smooth muscle cells expressed their contractile phenotype after 
treatment with the nanoparticles, where higher expressions of smooth muscle actin and 
calponin were noticed.  
A computational model of the nanoparticle drug delivery system using COMSOL 
Multiphysics was used to analyze different stent strut geometries. The model analyzed 
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the effect of the different geometries on the velocity, shear stress, and magnetic flux 
density and how these factors affect the capture efficiency of the nanoparticles.  
Ex vivo studies were performed using porcine coronary arteries to validate the 
results seen in vitro, with the cell culture studies, and in silico, with the computational 
modeling studies. Ex vivo studies were performed both statically and dynamically. The 
dynamic system included an organ culture bioreactor that simulated physiological 
conditions. The nanoparticle-treated arteries showed less neointimal thickening and 
higher expression of contractile properties than the control. The uptake of the 
nanoparticles was calculated. The arteries conditioned dynamically had particle capture 
efficiencies at day three that were comparable to the values predicted by the 
computational modeling studies.   
Future expanded ex vivo analysis should include a quantitative measure of 
neointimal hyperplasia. Patency calculations and PCR are recommended to further 
analyze the efficiency of the proposed drug delivery system. A large animal model study 
is needed to test the drug delivery system in vivo. The model should analyze the effect of 
the nanoparticles and the drug delivery system on neointimal hyperplasia, while also 
analyzing the toxicity of targeted delivery of the particles, in vivo.  
These studies should also analyze the uptake and efficiency of the nanoparticles 
over an extended period of time. All the studies discussed here did not extend past seven 
days due to limitation of the ex vivo setup. While treating neointimal hyperplasia in its 
early stages should limit the risk of restenosis, an extended in vivo study is recommended 
to ensure lasting effect of the proposed treatment. 
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There have not been enough studies to analyze how different stent geometries 
affect magnetically guided drug delivery systems. While the work in this dissertation 
shows that there are distinct differences due to stent geometries, expanded computational 
modeling to analytically analyze the effect of the different stent geometries on the 
magnetic field and magnetic flux density could be used to inform the choice of an ideal 
stent for the drug delivery system. This step could be incorporated into stent design 
workflows. 
A study to analyze the effect of heparinase on the release of the heparin on the 
nanoparticles needs to be analyzed. The release of heparin from the nanoparticles with 
and without heparinase could be analyzed over a period of time using DMMB, to confirm 
the release method of heparin.  
While stent use, clinically, has greatly advanced the treatment of cardiovascular 
diseases, we need new approaches to deal with long-term complications that arise from 
these approaches. Magnetic guided nanoparticle therapies provide a simple method for 
targeting drugs to stented areas and could have applications beyond what was presented 
here. 
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Appendix A 
Polymer Modification 
Written: Nardine Ghobrial 
 
1. The polymer was synthesized by the Mefford Group using a living anionic ring 
opening polymerization of ethylene oxide with potassium bitrimethylsilylamide as 
an initiator and methane sulphonyl chloride was used to terminate the reaction (1). 
2. In a round-bottom flask, add triethylamine and dopamine hydrochloride to the 
polymer in a 1.2:1.1:1 ratio, in 20 mL of dimethylformamide.  
3. Place reaction on a magnetic stir plate overnight. 
4. Add a few drops of hydrochloric acid to the reaction and let it stir for 4 hours. 
5. Take flask with polymer solution off stir plate. 
6. Put 20 mL polymer solution in 4X50 mL centrifuge tubes, 5mL each. 
7. Fill the rest of the tubes to the top with ethyl ether.  
8. Centrifuge for 7 minutes at 10,000 rpm. 
9. Pour supernatant out and add 5 more mL of polymer to each tube. 
10. Repeat steps 3, 4, and 5 until all the polymer solution is gone.  
11. Add 5 mL of chloroform to the supernatant in each tube and fill the rest of the 
tubes with ethyl ether. 
12. Centrifuge again for 7 minutes at 10,000 rpm. 
13. Poke holes in the caps of the centrifuge tubes using a needle and place them in 
vacuum oven to dry overnight. 
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Appendix B 
Magnetite Nanoparticle Synthesis 
Written: Nardine Ghobrial 
 
 
1. Combine 1.074 g iron acetylacetonate with 15 mL of oleic acid in a 3-headed flask. 
2. Cap the 2 side heads with rubber stoppers. 
3. Heat a metal bath to 370oC and place the flask on a holder in the metal bath. 
4. Carefully, attach a stir rod to the spinner and place it in the middle head of the flask 
and start spinning. 
5. Place nitrogen needle through the back stopper and adjust to 0.25 liter per minute. 
6. Let the reaction run for 4 hours then let it sit overnight. 
7. Separate magnetite solution into 3X50 mL centrifuge tubes. 
8. For each tube, add 5 mL hexanes and ethanol:acetone in a 5:1 ratio.  
9. Shake the tubes then use magnetic separation to discard the supernatant. 
10.  Repeat steps 8 and 9, 4 times then store in chloroform. 
11. Inject the particles suspended in chloroform at approximately 3 mg/mL into 
scintillation vile containing previously described PEO polymer suspended in 
chloroform at approximately 40 mg/mL, with a septum cap under sonication.  
12. The injection process is done over a 30-minute period then allow it to sit under 
sonication for another 30 minutes, then allow it to sit for 4 days. 
13. After four days, remove chloroform using rotary evaporation process. The 
nanoparticles are then resuspended into hexanes, sonicated, magnetically separated, 
and resuspended in chloroform and allowed to sit for 2 more days.  
14. Repeat step 13, 4 times. After rotary evaporation for the third time, the particles are 
suspended in DI water.  
15. Briefly sonicate the particles to ensure breaking any large aggregates, then pass them 
through a 0.22 µm nylon syringe filter.  
16. Centrifuge the particles at 10,000 RPM for 10 minutes, decant the supernatant, and 
disperse the nanoparticles in DI water.  
17. To get rid of excess polymer, the particles are filtered through 50 kDa centrifugal 
filter units (Millipore). 
18. Mix the amine-functionalized nanoparticles with heparin at a 1:3 molar ratio. The 
aqueous particle solution is added to a low molecular weight heparin (LMWH, MP 
Biomedical), N-hydroxysulfosuccinimide (sulfoNHS, Thermo Scientific), and 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, TCI Chemicals) 
solution, with excess sulfoNHS and EDC.  
19. Allow the solution to sit on a shake plate for 7 days to allow reaction. To get rid of 
excess LMWH, sulfoNHS, and EDC, the particles are filtered through 50 kDa 
centrifuge filter units. 
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Appendix C 
Fe Determination Protocol 
Written By: Elliot Mappus 
Updated: Andrew Hargett 3/21/16 
 
Iron Working Solution Preparation: 
1. Obtain desired iron sample for test. 
2. Transfer 5-8uL for concentrated samples or 100uL for dilute samples to a 
10mL volumetric flask with a calibrated 10uL pipette. Note: Use one of the 
short-necked flasks to allow the pipette to reach the bottom of the flask. Place 
drop in center. We found 50 uL to work well. 
3. Dissolve the iron in the flask with approximately 0.2mL of concentrated HCl 
for 15 seconds. 
4. Fill the flask with deionized water to the 10 mL mark to form the iron stock 
solution. Top with a ground glass stopper and mix by inversion 3 times. 
5. Transfer the solution to a disposable 15mL centrifuge tube and mix by 
inversion. 
 
Color Working Solution Preparation: 
1.Hydroxylamine hydrochloride solution (100 g/L) – dissolve 1 g of hydroxylamine 
hydrochloride in 10 mL nanopure water. 
2.1,10-phenanthroline solution (3 g/L) – dissolve 0.3 g of 1,10-phenanthroline 
monohydrate in 10mL of methanol and dilute to 100 mL with nanopure water. 
3.Ammonium acetate-acetic acid solution – dissolve 10 g of ammonium acetate in 
about 60 mL of wter, add 20 mL of glacial acetic acid, and dilute to 100 mL with 
nanopure water. Sodium acetate may be used in place of ammonium acetate. 
 
Sample Preparation: 
1. Using a calibrated 1mL pipette, transfer 0, 0.5, 1, 1.5, 2, and 2.5 mL of iron 
working solution to several 15 mL centrifuge tubes. 
2. Dilute each centrifuge to 6mL with deionized water. 
3. To develop color: 
a. Add 0.2 mL of hydroxylamine hydrochloride solution to each 
centrifuge tube and swirl to mix. 
b. Add 0.5 mL of 1,10-phenathroline solution to each centrifuge tube and 
swirl to mix. 
c. Add 0.75 mL of ammonium acetate-acetic acid solution to each 
centrifuge tube and swirl to mix. 
d. Dilute each tube to 10 mL with nanopure (DI) water using a pipette. 
Mix by inversion. 
4. Transfer 180 uL from each flask to a well in a 96-well plate. 
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Measure Absorbance: 
1. Measure all samples using a plate reader. 
2. For each sample, record the absorbance at 511 nm (the Fe peak) and at 690 
nm (the baseline). 
3. Subtract the 690 nm absorbance from the 511 nm absorbance and insert value 
into iron determination spreadsheet. 
 
Cleaning Procedure Notes: 
1. Glassware should be stored in the drying oven and rinsed twice with DI water 
following use. 
2. After stock solution is made, add 3 mL of concentrated HCl to the volumetric 
flask. Swirl for 30 seconds and dispose of the acid. 
3. Rinse Volumetric flask twice with water in the fume hood, then twice outside 
of the fume hood. 
4. Make the iron working solution immediately prior to measurements. 
5. Color working solutions may be made several months in advance. 
 
Reference: ASTM, E 394-0 
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Appendix D 
 DMMB Assay 
Written by: Alex Lindburg – MBEM Lab 
Updated: Andrew Hargett 3/21/16 
Updated: Nardine Ghobrial 2/28/2018 
 
DMMB Working Solution: 
1. Dissolve 16 mg of DMMB dye in 1 L of nanopure water. 
2. Add 3.04 g 99%+ pure glycine, 2.37 g NaCl, and 95 mL of 0.1 M HCol. 
3. Stir with a stir-bar to mix thoroughly. 
4. Filter through Watman paper, discard if there is any precipitate. 
5. This solution may be stored at room temperature and protected from light for 
up to 2 months. 
 
Standard Curve Generation: 
1. Make an initial working solution of 100 ug/mL GAG by adding 2.0 mg 
heparin powder to 20 mL of PBS. 
2. Dilute appropriately to make final GAG working solutions of 0, 10, 20, 30, 
40, and 50 µg/mL 
3. Add 180 µL of DMMB working solution to 18 wells of a U-bottom 96-well 
plate. 
4. Add 20 µL of GAG working solutions to wells in triplicates and shake for 5 
seconds. 
5. Read absorbance at 530 nm using a microplate reader. 
 
Reference: 
Mort, JS and PJ Roughly. Measurement of glycosaminoglycan release from cartilage 
explants. (2007) Methods in Molecular Medicine. 135, 201-209. 
 
Heparin Loading Calculation: 
1. Create working solutions of nanoparticles at 0, 100, 150, 200, and 250 µg/mL 
in water. 
2. Mix 20 µL of each nanoparticle working solution with 180 µL DMMB 
working solution in triplicates in a U-bottom 96-well plate. 
113 
3. Read absorbance using a microplate reader at 530 nm. 
4. Normalize the value of nanoparticle concentration to heparin concentration to get the 
concentration of µg heparin per µg nanoparticles. 
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Appendix E 
Cell and Tissue Fixation and Embedding Protocol for TEM 
Written by: Nardine Ghobrial 
 
1. Cells are grown in T-75 flasks and passaged according to standard protocol 
forming a pellet in a 15mL centrifuge tube. Tissues are placed in a centrifuge 
tube.  
2. Wash 3 times with buffer (cacodylate). 
3. Fixate with 3% glutaraldehyde for 1 hour (24 hours for tissues and larger cell 
pellets) at room temperature. 
4. Rinse for 5 minutes in buffer (cacodylate), 3X 
5. Add 1% osmium tetroxide with a few crystals of potassium ferrocyanide for 1 
hour (4-6 hours, or until all in brown for tissues and larger cell pellets) at room 
temperature. 
6. Dehydrate in ethanol in a series (50%-70%-95%-(2X)100%) for 4 (15) minutes 
each. 
7. Infiltrate in LR White  
• LRW : ethanol- 1:1  overnight (fridge) 
• LRW  3 hours (room temperature) 
• LRW  20-24 hours (oven at 600C) 
8. Utrathin sections (70-90 nm) are cut using a microtome.  
9. Sections are mounted onto copper grids, precoated with Formvar  
10. (Sections could be stained with uranyl acetate (30 minutes) and lead citrate (1 
minute)). 
11. TEM H7600 is used.  
12. For EDAX analysis, TEM 2000 could be used.  
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Appendix F 
Live/Dead Assay Protocol 
Written by: Andrew Hargett 
Updated: Nardine Ghobrial 6/26/2017 
 
Sample Preparation: 
1. Seed cells at 20,000 cells/well into a 24-well plate in standard media. 
2. Incubate in standard media check for cell attachment. 
3. Aspirate media and replace with experimental solutions and control 
parameters diluted in media in quadruplicates.  
5. Incubate for 72 hours or as desired and check for cell attachment. 
6. Aspirate media or experimental solutions and wash 3X with PBS. 
 
Live/Dead Assay: 
1. The Live/Dead Viability/Cytotoxicity kit by Life Technologies was used to 
create working solutions of calcein acetoxymethyl (Calcein) and ethidium 
homodimer-1 (Etd-1). 
2. Make solutions as follows: 
a. 20 ul ethD-1 + 5 ul calcein  20 ml PBS (50 ml centrifuge tube) 
b. 5 ul ethd-1  5 ml PBS (15 ml centrifuge tube) 
c. 2.5 ul calcein  10 ml PBS (15 ml centrifuge tube) 
3. Incubate all conditions for 30 min protected from light.  (room temp.) 
4. Measure fluorescence using a microplate reader at 485nm excitation to 530nm for live 
cell emission.  
5. Calculate % live cell according to manufacturer’s protocol. 
6. Image using an EVOS FL Microscope under Red/Green fluorescence for 
qualitative data. 
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Appendix G 
MTS Assay Protocol 
Written by: Andrew Hargett 
Updated: Nardine Ghobrial 7/11/2017 
 
Sample Preparation: 
1. Seed cells at 20,000 cells/well into a 24-well plate in standard media. 
2. Incubate in standard media check for cell attachment. 
3. Aspirate media and replace with experimental solutions and control 
parameters diluted in media in quadruplicates.  
5. Incubate for 72 hours or as desired and check for cell attachment. 
6. Aspirate media or experimental solutions and wash 3X with PBS. 
 
MTS Assay: 
1. Mix the working solution from a CellTiter Aqueous One Solution Cell Proliferation 
Assay kit by Promega with standard media in a ratio of 1:5 by volume. (3 ml assay + 15 
ml media in a 50 ml centrifuge tube wrapped in aluminum foil) 
2. Aspirate experimental media and wash with sterile PBS 2x.  
3. Add MTS solution diluted in media in same volume as experimental conditions. (600 
ul) 
4. Protect from light and incubate (in incubator) from 1-4 hours.  
5. Transfer the supernatant to a 96 well plate (in triplicates-180 ul each).  
6. Measure absorbance at 490 nm using a microplate reader. 
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Appendix H 
Immunofluorescence 
Written: Suzanne Bradley 
 
1. Fix cells using a 4% formaldehyde, 0.1% glutaraldehyde solution in 1X PBS for 20 
minutes at room temperature.  
2. Rinse gently 3 times with 1X PBS.  
3. Permeabilize cells with a 0.1% Triton X-100 solution in 1X PBS for 15 minutes at 
room temperature.  
4. Rinse gently 3 times with 1X PBS.  
5. Block cells using a 2% BSA, 3% goat serum solution in 1X PBS for 30 minutes at 
room temperature.  
6. Add primary antibody diluted in blocking solution 1:500, and incubate overnight at 
4°C.  
7. Save primary antibody for future uses.  
8. Rinse gently 3 times with 1X PBS.  
9. Add fluorescent secondary antibody at a concentration of 4 μL/mL in 1X PBS.  
4. Rinse gently 3 times with 1X PBS.  
5. Add 2.5% Alexa Fluor 568 Phalloidin (red) in 1X PBS for 20 minutes at room 
temperature.  
6. Rinse gently 3 times with 1X PBS.  
7. Add 300 nM DAPI solution (blue) in 1X PBS for 5 minutes at room temperature. 
8. Rinse gently 3 times with 1X PBS and store in PBS to image. 
9. Image with EVOS fluorescent microscope. 
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Appendix I 
Polymerase Chain Reaction  
Written: Matt Rusin 
 
 
Materials Needed 
• TRIzol® Reagent • Water bath or heat block at 55-60°C 
• Chloroform • TURBO DNA-free Kit 
• Isopropyl Alcohol • Applied Biosystems PowerUp SYBER 
Green Master Mix 
• 75% ethanol (in DEPC-treated water) • Applied Biosystems High Capacity 
cDNA Reverse Transcription kit 
• RNase-free water • Selected Primers 
• Centrifuge capable of reaching 12,000xg 
and 4°C 
• 96-well PCR plate and adhesive cover 
• Sterile microcentrifuge tubes (1.5mL 
and 0.5mL tubes) 
• RNase spray 
Preparing Samples 
1. Homogenizing Samples 
a. Passage cells according to proper protocol. 
i. Remove media, wash cells with 1X PBS, and add Tripsin (5mL per T75 
flask). 
ii. Incubate at 37°C for 5 minutes in order to fully detach all cells. 
iii. Add an amount of media equivalent to the amount of Tripsin used and 
transfer solution to a centrifuge tube. 
iv. Centrifuge for 5 minutes at 1000rpm. Remove supernatant. 
b. Add TRIzol® directly to the cell pellet, volume dependent on the size of the 
pellet 
i. 250µL is a good volume unless the cell pellet is very large. 
c. Lyse cells by pipetting solution up and down. “Mortar and pestle” sticks can 
also be used to assist breaking up the cells. 
d. (Optional) Store sample solutions in individual 1.5mL microcentrifuge tubes. 
Samples will be fine at room temperature for a couple hours, but if they will not 
be immediately used, store at -80°C. 
i. Do note store at -80°C for more than a month. RNA will begin to degrade, 
resulting in lower quality. 
2. Phase Separation 
a. Incubate homogenized sample for 5 minutes at room temperature. If samples are 
frozen, allow to thaw first. 
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b. Add 0.2mL of chloroform per 1mL of TRIzol® used for homogenization. Close 
cap. 
c. Shake tube vigorously by hand for ~15 seconds. Solution should turn cloudy 
pink. 
d. Incubate at room temperature for 2-3 minutes. 
e. Centrifuge samples at 12,000xg for 15 minutes at 4°C. 
i. The mixture separates into 3 distinct layers: lower red phenol-chloroform 
phase, an interphase, and a colorless upper aqueous phase. RNA will 
remain exclusively in the upper aqueous phase. 
f. Carefully remove the aqueous phase and pipet it into a new microcentrifuge 
tube. This is made easier by angling the tube at a 45° angle. 
i. DO NOT pull any of the interphase as it will contaminate the RNA. The 
interphase is a pink solid; if some is accidentally pulled into the pipet, 
slowly depress the plunger until it has been ejected 
3. RNA Precipitation 
a. (If cell count is under 1x106, start here) Add 5-10µg of RNase-free glycogen to 
the aqueous phase. 
i. Stock glycogen is at a concentration of 5mg/mL. Dilute to appropriate 
concentration. 
1. It is recommended to add 5-10µg. This translates to 2µL of stock 
solution. 
ii. Glycogen is co-precipitated with the RNA, but does not inhibit first-strand 
synthesis at concentrations ≤4mg/mL, and does not inhibit PCR. 
b. Add 0.5mL of 100% isopropanol to the aqueous phase, per 1mL of TRIzol® 
used for homogenization. Mix slightly. 
i. If no glycogen was used, incubate at room temperature for 10 
minutes. 
ii. If glycogen was used, incubate at -20°C for 10 minutes. 
c. Centrifuge at 12,000xg for 30 minutes at 4°C. 
i. RNA should be visible in a gel-like pellet at the bottom of the tube after 
centrifuging. 
4. RNA Wash 
a. Remove the supernatant, leaving only the RNA pellet. 
i. The pellet is stuck pretty well to the bottom of the tube, so it can be safe to 
dump the supernatant out. Be careful if you choose to do this instead of 
pipetting the liquid out. 
ii. With the cap open, let the pellets dry slightly (<1 minute) 
b. Wash the pellet with 100µL of 75% ethanol. 
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c. Vortex briefly, then centrifuge at 12,000xg for 10 minutes at 4°C. 
d. Remove liquid, careful to not disturb the pellet. 
e. Centrifuge for 30 seconds. 
i. This consolidates all remaining liquid. 
ii. Remove liquid, again careful to not disturb the pellet. 
f. Air dry with the caps open, keeping a close eye on the pellets. 
i. As they dry, they will become more gel-like and start to disappear. If the 
pellet dries too much, the RNA will degrade. It should take around 5 
minutes for drying to occur, but each pellet will be different. 
5. RNA Resuspension and DNase Treatment 
a. Resuspend pellet in 20µL DNase and RNase free water, pipetting up and down 
a couple times to break pellet apart. 
b. Incubate in a water bath or heat block at 55-60°C for 10-15 minutes. 
c. Add 3µL 10x Turbo DNase Buffer; pipet up and down to distribute. 
d. Add 1µL Turbo DNase; pipet up and down to distribute. 
e. Incubate at 37°C for 30 minutes. 
f. Add 3µL DNase Inactivation Agent; pipet up and down to mix. 
g. Incubate at room temperature for 5 minutes, flicking occasionally to mix. 
h. Centrifuge at 10,000xg for 1.5 minutes. 
i. Transfer liquid to a 0.5mL centrifuge tube. 
i. Be extremely careful not to disturb the pellet at the bottom as it will 
contaminate the sample. 
6. RNA Quality Check: Nanodrop 
a. Place 4µL RNA-free H20 on pedestal for ~5 minutes. Wipe clean with 
Kimwipe. 
b. Open the Nanodrop and follow instructions for calibration. Change “Type” to 
RNA (on the left side of the screen). 
c. Blank the machine by placing 2µL RNA-free H20 on pedestal and pressing 
“Blank”. The graphical result should be very close to 0. 
d. Measure the blank, then wipe clean. 
e. Measure each sample (2µL), being sure to label each in the software before 
measurement. 
i. Good quality is shown by the A260/280 value being above 1.8. Below 1.6 
is considered bad quality and should not be used for cDNA expansion or 
genomic analysis. 
f. Export the data to a spreadsheet. Columns of interest include Samples ID, 
Nucleic Acid Concentration, A260, A280, and 260/280. 
g. Place 4µL RNA-free H20 on pedestal for ~5 minutes in order to clean again. 
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7. cDNA Expansion and Reverse Transcription 
a. Remove cDNA Reverse Transcription Kit from freezer and allow to thaw. 
b. Prepare master mix from kit.  
Component Volume/Reaction (uL) 
 Kit with RNase 
Inhibitor 
Kit without RNase Inhibitor 
10X RT Buffer 2.0 2.0 
25X dNTP Mix 
(100mM) 
0.8 0.8 
10X RT Random 
Primers 
2.0 2.0 
MultiScribe™ Reverse 
Transcriptase 
1.0 1.0 
RNase Inhibitor 1.0 - 
Nuclease-free H2O 3.2 4.2 
Total per Reaction 10.0 10.0 
Important: Include ~10% additional volume in the calculations to provide 
excess volume for the loss that occurs during reagent transfers. 
c. Calculate volume of water to add to RNA to achieve desired concentration. 
i. 200ng of total RNA is sufficient for reliable results. 
d. Pipette 10uL of master mix into each vial. 
e. Pipette calculated amount of RNA into each vial, then add Nuclease-free H2O 
until total volume is 20uL. Pipette up and down a couple times to mix. 
f. Place samples in the thermal cycler using the following settings 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Time 10 min 120 min 5 min ∞ 
 
8. SYBR Green and Primer Preparation 
a. Thaw DNA samples and primers. Vortex to mix thoroughly. 
b. Swirl SYBR Green Master Mix to mix thoroughly. 
c. Determine volume amounts needed for each primer master mix (including at 
least 3 replicates), then add 10% to account for pipetting error. 
Component Volume (20µL/well) 
SYBR Green Master Mix 10µL 
Forward and Reverse Primers Variable (2-4µL) 
DNA template 2µL 
Nuclease-Free Water Variable 
Total 20µL 
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d. Mix components of each master mix thoroughly by vortexing. If there are any 
bubbles present, centrifuge briefly. 
e. Transfer the correct volume of each master mix to the appropriate wells of an 
optical plate. 
f. Seal the plate with an optical adhesive cover, then briefly centrifuge the plate to 
remove any air bubbles. 
g. Plate can be stored at room temperature for up to 24 hours and still obtain 
reliable results. 
9. Setup and running the PCR instrument 
a. Turn on the StepOne Plus. It will take 10-15 minutes for the instrument to 
properly warm up and connect to the software. 
b. Place the plate in in the instrument. 
c. In the software, select “Advanced Setup”. 
i. Define your targets (primers) and your samples. 
ii. Setup the plate by defining where each target and sample is located. 
iii. Setup the run protocol. This is determined by a combination of the SYBR 
Green being used and melting temperature of the primers. Each SYBR 
Green kit should have a couple tables to help you figure out the proper 
temperatures to use. Determining the melting temperature of the primers is 
a little more involved, though, and might require some trial and error to 
nail down. 
iv. Ensure that a melt curve is being generated at the end so you can be 
confident that your primers are acting correctly. 
d. Start the run. 
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Appendix J 
TEM Uptake Study 
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Day 2 Day 3 
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Appendix K 
Hematoxylin and Eosin Staining protocol 
Written: Jayesh Betala  
Updated: Nardine Ghobrial 
 
For paraffin embedded tissues start here:  
 
1) 10 dips in xylene for deparaffinizing 
2) 5 minutes in xylene  
For GMA embedded tissue start here: 
3) 10 dips in 100% ethanol followed by 1 minute in 100% ethanol  
4) 10 dips in 95% ethanol followed by 1 minute in 95% ethanol  
5) Rehydrate in tap water for 1 minute followed by 1 minute in distilled water  
6) 5 minutes in hematoxylin solution followed by rinsing under tap water until clear  
7) 4 dips in clarifier, clear under tap water followed by bluing reagent for 1 minute and 
again rinsing under tap water  
8) Dehydrate in 95% ethanol for 30 seconds, followed by 30 seconds in eosin  
9) Dehydrate in 95% ethanol- 10 dips, 100% ethanol- 10 dips, 100% ethanol – 1 minute 
and 100% ethanol – 3 minutes  
10) Clear in xylene with 10 dips and 5 minutes incubation.  
11) Mount with a mounting medium, coverslip and image under microscope  
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Appendix L 
Masson’s Trichrome Staining protocol 
Written: Jayesh Betala  
Updated: Nardine Ghobrial 
 
For paraffin embedded tissues start here:  
1. 10 dips in xylene for deparaffinizing 
2. 5 minutes in xylene  
For GMA embedded tissue start here: 
3. 10 dips in 100% ethanol followed by 1 minute in 100% ethanol  
4. 10 dips in 95% ethanol followed by 1 minute in 95% ethanol  
5. Rehydrate in tap water for 1 minute followed by 1 minute in distilled water  
6. Mordant in Bouin’s solution for 1 hour at 60⁰C. Wash in running tap water for 5 
minutes 
7. Stain in Weigert’s Iron hematoxylin working solution for 10 minutes (Working 
solution prepared by mixing solution A and Solution B at 1:1 ratio) 
8. Wash in running tap water for 5 minutes, followed by distilled water for 1 minute. 
9. Stain with Biebrich Scarlet- Acid Fuchsin solution for 5 minutes followed by 
rinse in distilled water 
10. Treat with Phopsphotungstic/Phosphomolybdic acid for 10 minutes (Do not rinse 
with distilled water at this step) 
 
 
11. Stain with Aniline Blue solution for 5 minutes followed by at least 2 rinses in 
distilled water  
12. Differentiate with 1% acetic acid for 30 seconds and rinse in distilled water  
13. Dehydrate in 95% ethanol, 100% ethanol and clear in xylene for 5 minutes 
14. Mount with mounting medium and coverslip and image under a microscope  
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Appendix M 
GMA Embedding Protocol 
Written: Nardine Ghobrial 
 
1. Wash tissue in PBS then fix in 10% formalin for 24 hours.  
2. Wash fixed tissue in saline then rinse in 100% ethanol for 5 minutes. 
3. Place tissue in tissue cassettes in GMA inside a glass dessicator, under vaccum in 
the fridge for 2 weeks 
4. After 1 week, filter GMA and replace it. 
5. Place tissue in a tear-away mold in GMA under ultravilot light for 24 hours to 
cure. 
6. Section the GMA blocks were cut into sections of ~5 mm in thickness using a 
band saw.  
7. Glue the GMA sections to plexiglass slides then polish to ~80-120 µm sections 
using a grinding wheel.  
 
 
 
 
